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CHAPTER 1: INTRODUCTION 
 
1.1  Breast cancer 
1.1.1 Definition and subtypes 
The main subtypes of breast cancer were originally identified via DNA microarray and were 
categorised into luminal A, luminal B, human epidermal growth factor receptor (HER2) 2- 
positive, basal-like, claudin-low and normal-like subtypes.
1-3
 Luminal subtypes were all known 
to be oestrogen receptor (ER) – positive. Luminal A tumours were low-grade with progesterone 
receptor (PR) – positive and HER2 – negative features. Luminal B tumours were of higher grade, 
PR-positive or PR-negative and either HER2-positive or HER2- negative.
4
 About 13 – 20% of 
invasive breast tumours had shown HER2-positivity which were treated with trastuzumab, a 
humanised anti-HER2-specific monoclonal antibody. Claudin-low subtypes usually had low to 
absent expression of luminal markers, abundant epithelial-to-mesenchymal transition markers, 
immune response genes and cancer stem cell-like features.
5
 
 
Basal-like breast cancer, on the other hand, has drawn many controversial discussions over its 
proper pathological definition due to the heterogeneous nature of the disease. So far, it has been 
defined in both immunohistochemical and deoxyribonucleic acid (DNA) microarray-related 
perspectives and there was yet no internationally-accepted definition. Basal-like breast cancer 
possessed triple-negative markers which meant that these basal-like tumour cells were HER2-
negative, ER-negative and PR-negative when examined in DNA microarray analysis. The 
immunohistochemical features for these tumour subtypes consisted of cytokeratin 5/6-positive 
12 
 
and/or epidermal growth factor receptor-positive. Because of the presence of the triple-negative 
markers for basal-like breast cancer, it could be ambiguously referred to as triple-negative breast 
cancer. However, after extensive studies were done it was shown that these two cancer subtypes 
were not synonymous as there were some overlaps in the disease features between these two 
subtypes of breast cancer.
1,2,6
 To further emphasise the heterogeneity of breast cancer, it was also 
found that about both basal-like breast cancer and BRCA1-mutated tumours shared many 
common features and about 75% of BRCA1-related tumours were discovered to be basal-like 
breast cancer. 
7,8
 
 
1.1.2 Current chemotherapy for basal-like breast cancer  
 
Basal-like breast cancer is the most aggressive breast cancer subtype with the poorest prognostic 
outcome.
1,9
 It is more likely to occur in pre-menopausal women who are younger than 40 years 
of age. Currently there are very minimal specific and effective treatment agents available to 
target basal-like breast cancer. It has a poor response to most of the conventional chemotherapies 
used to treat other breast cancer subtypes.
1,10
 From recent reviews on the treatment of basal-like 
breast cancer, it is confirmed that conventional chemotherapy and/or DNA damaging agents for 
the duration of at least four to six months is the best possible treatment regimen to date for basal-
like breast cancer patients.
9,11
 Several other single agents such as bevacizumab, polyadenosine 
diphosphate-ribose polymerase inhibitors or agents targeting epidermal growth factor receptor 
are presented with conflicting results after trials in triple-negative breast cancer. 
 
13 
 
 
1.2 Calcium signalling mechanism and calcium homeostasis 
Calcium (Ca
2+
) is an important signalling agent coordinating a variety of physiological processes 
in the body.
12
 The signalling role of calcium was first discovered by serendipity in 1883 where 
isolated rat hearts were found to contract in hard water rather than in distilled water.
13
 Further 
signalling roles were later investigated and numerous cellular processes such as cell fertilisation, 
proliferations and apoptosis were found to have calcium involved as the essential messenger.
13
 
Ca
2+
 signalling are crucial for a vast amount of cellular functions such as short-term responses in 
contraction and secretion and longer-term control of transcription, cell division and apoptosis.
14
 
In order to achieve balanced calcium signalling processes in our body, calcium homeostasis is 
required to be maintained at all time as it is also a critical step for cell survival.
15
 
 
There are two main sources of signal calcium which are from the internal cellular stores and 
external medium.
15
 The internal stores are mainly kept in the sarcoplasmic reticulum (SR) or 
endoplasmic reticulum (ER) where the signal calcium are controlled either by calcium itself or a 
group of messengers such as inositol-1,4,5-triphosphate (Ins(1,4,5)P3), cyclic adenosine 
diphosphate (ADP) ribose, nicotinic acid adenine dinucleotide phosphate or sphingosine-1-
phosphate. The external medium consists of the plasma-membrane channels which will control 
the entry of calcium ion by responding to various stimuli, for example, membrane depolarisation, 
stretch, noxious stimuli, extracellular agonist action, intracellular messaging or depletion of the 
intracellular calcium stores.
15
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1.2.1 Membrane proteins for calcium homeostasis 
During the “ON” reaction where Ca2+ is introduced into the cells, Ca2+ enters mainly from the 
external medium across a large electrochemical gradient through the plasma membrane and 
activates various entry channels during the process.
15
 Other sources of Ca
2+
 entry during the 
reaction are from the existing internal stores from the SR or ER where the calcium entry is 
regulated by Ins(1,4,5)P3 and ryanodine receptors. To counteract the “ON” reaction, an “OFF” 
reaction for the calcium homeostasis is necessary to be in place in order to switch off the calcium 
signal within the cytoplasm to avoid excessive accumulations of Ca
2+
. In order to achieve the 
“OFF” reaction, there are four main pumps and exchangers acting as the tools for carrying out 
this process. These are the sodium/calcium exchangers, plasma-membrane Ca
2+
-ATPase 
(PMCA), sarcoplasmic or endoplasmic reticulum calcium ATPase (SERCA) and the 
mitochondrial uniporter.
13,15
 By maintaining a calcium homeostasis in the cells, the resting level 
of Ca
2+ 
is at about 100nM in the cytoplasm. 
 
1.2.2 Store-operated calcium entry 
Store-operated calcium entry (SOCE) was one of the many important cellular functions involved 
in many non-excitable and excitable cells.
14,16
 SOCE was vital in cell proliferation, apoptosis and 
differentiation. It was also involved in cellular shape changes and regulation of T cell motility. 
Other roles of SOCE in cellular functions also included regulation of cellular secretion and 
neurotransmission. It was a process involving the depletion of intracellular Ca
2+
 in the ER store 
which then triggered the influx of Ca
2+
 from the extracellular space through store-operated 
channels (SOCs). An early example was shown by using thagpsigargin (TG) as a molecular 
probe for understanding the intracelluar Ca
2+
 storage and release.
17
 It demonstrated that SERCA 
15 
 
inhibition took place when TG was present and blocked the reuptake of Ca
2+ 
into the ER. This 
then caused a slow-emptying of the ER Ca
2+
 store which then induced SOCE.  
  
 
 
 
 
 
 
 
 
 
The ER Ca
2+
 store depletion takes place as the remaining Ca
2+
 in ER slowly leaks out from the 
IP3R channel eventually emptying the Ca
2+
 store in the ER, while SERCA can be blocked by TG 
inhibiting the re-sequestration of Ca
2+
 (Figure 1)
16,18
. Similar SOCE effect would also occur 
with other SERCA inhibitors such as cyclopiazonic acid (CPA).
18
 Another commonly known 
example of SOCE occurred when G protein-coupled receptors on the plasma membrane were 
activated which in turn would induce Ins(1,4,5)P3 to activate the inositol-1,4,5-triphosphate 
receptor (Ins(1,4,5)P3R) on the ER. Ins(1,4,5)P3R would then begin the release of the ER Ca
2+
 
Figure 1  Different types of Ca
2+
 pumps involved in Ca
2+
 homeostasis (taken from ref. 16)  
16 
 
store. The depleted Ca
2+
 store would trigger a message to be sent to plasma membrane allowing 
the entry of extracellular Ca
2+
 via SOCs. In a different scenario but within the same principle, 
SOCE would also be induced as the stromal interacting molecule (STIM1) detected the depletion. 
STIM1 would aggregate or translocate to ORAI1, which was a plasma membrane Ca
2+
 influx 
protein associated with SOCE. ORAI1 would then activate the entry of Ca
2+
 from extracellular 
space (Figure 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2  Store-operated Ca
2+
 entry involving ORAI1 and STIM1 (taken from ref. 16)   
17 
 
1.3 Calcium ATPases 
 
1.3.1 Sarcoplasmic/endoplasmic reticulum calcium ATPase 
The involvement of adenosine triphosphate (ATP) in the calcium signalling process was first 
identified in the 1960s where Ebashi et. al.
19,20
 and Hasselbach et. al.
21
 found sarcoplasmic 
reticulum vesicles accumulated Ca
2+ 
by using ATP as their energy source.
13
 The transporters 
involved in actively transporting the cations across the cell membrane are named the 
phosphorylation-type (P-type) ATPases since they form a covalent aspartylphosphate group via 
the pyrophosphate bond of the ATP.
22,23
 They have originally evolved from two ancestral types 
where Type I P-type ATPases transport heavy metals such as Cu
+
, Cd
2+
 and Hg
2+
 and Type II 
transport lower atomic mass metals like Na
+
, K
+
, Ca
2+
 and H
+
.
24
 Calcium ATPase is a member of 
this P-type ATPase family.  
 
Calcium ATPases are comprised of SERCA, PMCA and Secretory Pathway Ca
2+
-ATPase 
(SPCA). SERCA remains the most extensively studied calcium ATPase, and the majority of the 
structural studies on SERCA structure has been done by Toyoshima 
25-34
 who has prepared and 
analysed the crystal structures of SERCA sourced from rabbit muscles. This has greatly assisted 
in understanding the relationship between its structure and function and also the mechanism of 
this calcium pump.
29
 SERCA is found to be embedded in the cell membrane of sarcoplasmic or 
endoplasmic reticulum with a relative molecular mass of 110,000. Its structure consists of three 
domains in the cytoplasmic part of the SERCA and ten transmembrane α-helices named M1 to 
M10 (Figure 3).
29,30
 The anchor or actuator domain (domain A) is the smallest domain out of all 
three domains. It has about 110 amino acid residues located between M2 and M3 with long loops 
18 
 
connecting to the transmembrane region. The nucleotide domain (domain N) is the largest 
domain headpiece present. It has seven-stranded antiparallel β-sheet with the critical ATP-
binding residue, Phe487, found within this region. Phosphorylation domain (domain P) is 
situated between domain A and N and is important as it processes the ATP phosphorylation site. 
Another important residue involved in the phosphorylation process, Asp351, is situated at the C-
terminal end of the central β-strand close to M5.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3  Structure of SERCA displaying three domains (A, N and P) with 10 transmembrane helices 
(M1 – M10) (taken from ref. 27) 
 
There are two Ca
2+ 
binding sites present in the M4, M5, M6 and M8 region.
29,30
 Ca
2+
 binding site 
one is contributed by the side-chain oxygen atoms of five residues (Asn768, Glu771, Thr799, 
19 
 
Asp800 and Glu908) on M5, M6 and M8. Site two is almost on the M4 helix where six residues 
(Val304, Ala305, Ile307, Asn796, Asp800 and Glu309) are involved in forming the binding site. 
Asp800 is a critical residue involved in the binding of both Ca
2+
 atoms. The binding sites are 
stabilised by extensive hydrogen-bond networks amongst the participating residues and also the 
transmembrane helices.  
 
During the muscle relaxation phase, SERCA pumps Ca
2+ 
from the cytoplasm into the reticulum 
which is known as the E1 phase of the E1-E2 model. The E1-E2 model shown in Figure 4 is also 
known as the Post-Albers cycle.
30,35-37
 It involves the phosphorylation of one ATP with two Ca
2+
 
transferred across the membrane. Initially the two Ca
2+ 
or ATP from the cytoplasm bind to the 
E1 conformation of the SERCA. This transforms the calcium ATPase into a high-energy 
phosphointermediate (2Ca
2+
-E1-ATP). Phosphorylation then follows to produce an ADP 
sensitive and another high energy intermediate (2Ca
2+
-E1-P). The next conformational change 
takes place to reach the E2 phase and forms the ADP insensitive and low energy intermediate 
(2Ca
2+
-E2-P). At this point the calcium-binding sites switch to face the luminal side and the two 
Ca
2+ 
and phosphate are released to bring the calcium ATPase back to the E1 phase. During the 
whole process two or three H
+
 are also counter-transported.
23
 This phosphorylation cycle is a 
classic characteristic of the P-type ATPases.  
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CYTOSOL 
 
E1 2Ca
2+
-E1-ATP 2Ca
2+
-E1-P 
   
   
E2 E2-P 2Ca
2+
-E2-P 
 
LUMENAL 
Figure 4  Post-Albers cycle showing the transition between E1 to E2 states of P-type ATPases 
 
SERCA is coded by genes ATP2A1, ATP2A2 and ATP2A3.
12
 There are three main SERCA 
isoforms present from alternative gene splicing and this gives rise to SERCA1a and 1b, 
SERCA2a, 2b and 2c and SERCA3a, 3b, 3c, 3d, 3e and 3f subtypes. Each SERCA isoform are 
expressed in different types of tissues, for example, SERCA1a and 1b are present in fast-twitch 
skeletal muscle, whereas SERCA2a are mostly found in the brain, cardiac, slow-twitch and 
smooth muscle cells.
12,24
 SERCA2b is expressed in all tissue types and 2c are found in epithelial, 
mesenchymal and haematopoietic cells. SERCA3a, 3b, 3c and 3e are in most tissues and some 
can be discovered in haematopoietic cells, salivary glands, trachea, lung, pancreas, kidney and 
colon.  
 
 
 
 
2Ca2+ 
ATP ATP ADP 
ADP sensitive 
High energy intermediate 
2Ca2+ H2O P ADP insensitive 
Low energy intermediate 
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1.3.1.1 SERCA inhibitors 
1.3.1.1.1 Cyclopiazonic acid 
Cyclopiazonic acid (CPA) 1 (Figure 5) is an indole tetramic acid metabolite of Aspergillus and 
Penicillium.
38,39
 It inhibits SERCA with high specificity and affinity. The mechanism of 
inhibition is implemented by blocking the calcium access channel
 
and making the structures of 
the involved transmembranes rigid and hence immobilised.
40
 The CPA binding site involves 
amino acid residues from M1, M2, M3 and M4 (Leu61 and Val62 from M1, Asn101 and Ala102 
from M2, Gly257 from M3, Leu311 and Pro312 from M4). The structure of CPA consists of two 
main regions, the tetramic acid portion and a hydrophobic region containing an indole nucleus. 
This indole nucleus is important for exerting the inhibitory effect of CPA as it bridges from M1 
to M4 helices. Removal of this indole nucleus eliminates the inhibiting effect of CPA.
41
 
 
 
 
 
 
 
 
1   2 
Figure 5  Structure of CPA           Figure 6  Structure of TG 
 
 
22 
 
1.3.1.1.2 Thapsigargin 
Thapsigargin (TG) 2 (Figure 6) is a naturally occurring sesquiterpene lactone compound, 
normally derived from Thapsia garganica.
42,43
 It has been found to inhibit ER Ca
2+ 
ATPase with 
high potency. This is largely observed when the intracellular Ca
2+ 
store increases after TG is 
added to rat liver microsomes. TG also inhibits SR Ca
2+ 
ATPase obtained from rabbit skeletal 
muscle.
44
  This is achieved by using a subnanomolar concentration of thapsigargin to produce the 
total inhibition of SR Ca
2+ 
ATPase.  As a result, TG is the most potent and specific SERCA 
inhibitor since the same effect was not observed in PMCA in erythrocytes.  
 
A crucial amino acid residue within SERCA, Phe256, is discovered to render TG ineffective 
when it is mutated.
45
 The effect occurs when Phe256 mutates to Leu256 in a Chinese hamster 
lung fibroblast cell line after it is subjected to different TG concentration treatments.
45
 The cell 
line developed resistance to the TG inhibition of the Ca
2+
 transport function within the cell. A 
similar TG-resistant effect also occurs in the Syrian hamster smooth muscle cell line within the 
same study where Phe256 mutates to Ser256.
45
 These evidences suggest that Phe256 is a critical 
amino acid residue in the SERCA and TG interaction.  
 
Another study has conducted F256V mutations in all three isoforms of SERCA (1b, 2b and 3a) 
expressed in COS-7 cells which are treated with four different SERCA inhibitors, TG, CPA, 2,5-
di-(
t
butyl)-1,4-benzohydroquinone (BHQ) and 4-n-Nonylphenol (NP)
46
. TG sensitivity is noted 
to vary in different SERCA isoforms and after the F256V mutation, TG sensitivity reduces 
across all three isoforms, but with variable results among them. Other SERCA inhibitors such as 
23 
 
CPA, BHQ and NP are only modestly affected by the F256V mutation. This indicates these 
inhibitors bind to a different hydrophobic site than TG. TG typically binds to M3 (Phe256), M5 
(Ile765) and M7 (Tyr837) helices.
43
 
 
1.3.1.2 SERCA-related diseases - Darier disease and Brody’s disease 
One of the documented cases of SERCA-related diseases was in 1969 involving a reduced Ca
2+ 
uptake by SERCA.
47
 The symptoms in individuals with this defect included muscle stiffness 
during exercises and painless cramps, this became known as Brody’s disease. Its main feature 
involved a slow muscular relaxation phase which caused the unusual muscle stiffness during 
exercise. Biopsy evidence was also found in quadriceps and cultured muscle cells in Brody’s 
disease patients with reduced SERCA1 pump activity.
48,49
 The reduced SERCA1 pump activity 
was not only found in slow-twitch but also in fast-twitch muscles in some clinical studies.
49
 
Another SERCA-related disorder is Darier-White disease, also known as Darier’s disease or 
keratosis follicularis 
50
. Darier’s disease is known to be a rare autosomal dominant skin disorder 
and was discovered earlier than Brody’s disease. It involved seborrhoic papules in upper trunk, 
scalp, palmar pits and other skin flexures. The major histological observation was the loss of 
epidermal cell adhesions and abnormal keratinisation due to mutations in genes encoding 
SERCA pumps. 
 
1.3.2 Plasma membrane calcium ATPase (PMCA) 
The structure of PMCA was predicted to be similar to SERCA with ten transmembrane helices 
and also the three A, N and P domains.
12,51
 There are no PMCA protein structures solved to date 
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but comparative modelling has been used to build the tentative PMCA structure based on the 
known protein structures of SERCA and protein sequence of PMCA. This however is still 
insufficient to inform the actual mechanism of its long C-terminal tail which was known to be 
involved in two different conformational states of PMCA. The location of PMCA as suggested 
by its name was mainly on the plasma membrane of the cells and was first discovered in 1966 
from erythrocytes.
52
 PMCA was coded by four different genes which have undergone alternative 
splicing at two sites of its protein sequence to produce four different PMCA isoforms, PMCA1, 2, 
3 and 4.
12,51
 The location of each isoform differed where PMCA 1 and 4 were expressed 
ubiquitously and type 2 and 3 were mainly restricted to the brain. Some of the PMCA2 were also 
found in mammary gland tissues and some PMCA3 in skeletal muscles. 
 
Calmodulin is known to activate and regulate PMCA activity as it increased the Ca
2+ 
binding 
affinity to the pump.
51
 PMCA pumps are also known to be activated by acidic phospholipids 
such as phosphatidylserine, cardiolipin, phosphatidylinositol and phosphatidic acid but its 
physiological significance is yet unknown.
53
 Another agent, calpain, was also found to activate 
PMCA pump irreversibly via cleaving the C-terminal tail.
12,51
 On the other hand, there were no 
known PMCA inhibitors comparable to TG for SERCA pumps. However, one suggested PMCA 
inhibitor was the caloxin peptides which were found to bind to the extracellular domain of 
PMCA and had selective inhibitory effect on different PMCA isoforms.
54
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1.3.2.1 PMCA-related diseases 
The four isoforms of PMCA also had their own individual impact on disease pathology. Since 
PMCA1 was distributed widely in the tissues, it has crucial effects on embryonic development 
and organogenesis. Other interesting findings also linked PMCA1 to human systolic blood 
pressure and coronary artery disease.
55,56
 PMCA 4, on the other hand, did not affect the 
embryonic development as far as PMCA1 and instead has more impact on male fertility.
57
 
Defects in genes encoding PMCA4 were likely to reduce sperm motility which led to sterility in 
males. PMCA4 was also found to regulate cardiac contractility in both in vitro and in vivo 
studies.
58,59
 As alluded to previously, PMCA2 were mainly concentrated in the central nervous 
system, especially in the cerebellum. It was thus expected to observe some central nervous 
system related problems when there were defects or mutations in the PMCA2 genes. One of such 
problems was discovered in PMCA2 mutant mice with ataxic symptoms found in standing and 
walking. PMCA2 gene mutations were also associated with deafness in some human cases.
60,61
 
Similar to PMCA2, PMCA3 is mainly distributed in the central nervous system and has been 
found to be related to a familial X-linked congenital cerebellar ataxia in PMCA3 mutation.
62
 
 
1.3.3 Secretory pathway calcium ATPase 
A new subset of calcium ATPase was first discovered in yeast, Saccharomyces cerevisiae.
63
 Two 
genes, PMR1 (plasma membrane ATPase-related 1) and PMR2 (plasma membrane ATPase-
related 2), isolated from the yeast were found to encode the calcium pump in the secretory 
pathway. The location of the yeast calcium pump is identified in the Golgi apparatus where ATP 
is required for calcium transport.
64
 Similar finding has also been shown by Sorin where yeast 
lysate fractions were assayed and PMR1 in the fractions was found to contain Golgi marker, 
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guanosine diphosphatase.
65
 Other supporting evidence includes when SERCA inhibitors such as 
TG, CPA and vanadates did not inhibit PMR1 Ca
2+ 
ATPase with the same intensity as that in 
SERCA. Another study has also characterised a PMR1 homologue in Caenorhabditis elegans. 
The PMR1 proteins expressed in COS-1 cells have accumulated Ca
2+
 and manganese (Mn
2+
) in 
the Golgi apparatus.
66
 A subsequent study was conducted in mammalian cells and the presence 
of PMR1 was confirmed with similar inhibitor sensitivities as the previous study in 
Caenorhabditis elegans.
67
 
 
This new subgroup of Ca
2+ 
ATPase was later named SPCA in humans.
68
 This is in line with the 
nomenclature and phylogenetic tree for SERCA and PMCA. SPCA is localised to the Golgi 
which is responsible for the modification and transport of proteins and biosynthesis of lipids.
69
 
One of the major functions of SPCA is Ca
2+ 
and Mn
2+
 transport into the secretory pathway.
68
 
Mn
2+
 transport is important for protein glycosylation, especially N-linked and O-linked 
glycosylations.
70
 SPCA also helps with cytosolic Ca
2+
 signalling as demonstrated in HeLa cells 
with SPCA1 inhibition via RNA-mediated interference.
71
 
 
There are two human genes, ATP2C1 and ATP2C2, encoding for SPCA which gives two SPCA 
subtypes; SPCA1 and SPCA2.
72
 ATP2C1 undergoes alternative splicing at the 3’-end of the 
primary mRNA and this gives rise to four different SPCA1 isoforms, SPCA1a, 1b, 1c and 1d. 
Newer SPCA isoforms such as SPCA1e and SPCA1f have also been identified recently.
73
 
SPCA2, on the other hand, only exists in one isoform as ATP2C2 does not undergo alternative 
splicing. SPCA2 has been investigated to possess the same ability as SPCA1 to transport Ca
2+
 
and Mn
2+
 without being affected by thapsigargin.
74
 The tissue expressions for human SPCA2 are 
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in the gastrointestinal and respiratory tract, prostate, thyroid, salivary and mammary glands. 
SPCA1 is mainly found in human epidermal keratinocytes and also in most of other tissues such 
as brain, heart, lungs and kidneys.
75
 
 
1.3.3.1 SPCA-related disease – Hailey-Hailey disease 
A well-known example of an inherited autosomal dominant disease resulted from ATP2C1 
mutation is Hailey-Hailey disease (HHD).
75,76
 HHD was characterised by skin blistering and 
erosions in carriers of the mutation. Human epidermal keratinocytes gathered from the carriers of 
ATP2C1 mutation have revealed inadequate intracellular Ca
2+
 regulation under both resting and 
stimulated states. This potentially affected the keratinocyte cell-to-cell adhesions leading to 
HHD’s clinical symptoms. This was also one of the examples of a clinical disorder related to 
mutations in human Ca
2+ 
ATPase. Another well-known disorder related to impaired Ca
2+
 ATPase 
was the aforementioned Darier’s disease which also shared similar clinical symptoms. It was 
therefore justifiable to state that both SERCA and SPCA pumps were essential for regulating and 
maintaining Ca
2+
 homeostasis in keratinocytes. Disruption to these Ca
2+
 pumps and thus the Ca
2+
 
homeostasis would likely lead to these diseases. This link was demonstrated when a loss of a 
functional allele of human gene, hSPCA1, was found to relate to HHD.
68
 
 
1.3.3.2 Role of calcium signalling in cancer 
More recent findings have subsequently found an important link between calcium signalling and 
cancer. Calcium signalling can regulate tumourigenesis, enabling cancer cells to escape 
apoptosis and maintain angiogenesis to assist cancer metastases.
77,78
 Two studies have 
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demonstrated this link via producing heterozygous mutations of ATP2A2 encoding SERCA2 in 
mice. This has resulted in squamous cell tumours in the murine skin, oesophagus, oral mucosa 
and stomach.
79,80
  Another study looks at the effect of mutating ATP2C1 encoding SPCA1 in 
mice.
81
 Similar effect has resulted where adult mice with heterozygous ATP2C1 gene 
expressions developed squamous cell cancers without any evidence of HHD. Cases of calcium 
signalling related to some cancers were also identified in remodelled PMCA isoform 
expressions.
78,82,83
 It was found that altered Ca
2+
 efflux ability would reduce the sensitivity of the 
cells to apoptosis and increase the response of cancer cells to cellular proliferative stimuli. 
PMCA1 and 4 were found to be highly expressed in breast cancer cell lines such as MCF-7 and 
MDA-MB-231.
84-86
 Silencing of PMCA4 facilitated the apoptosis of MDA-MB-231 cells 
mediated by the Bcl-2 inhibitor ABT-263 which was being evaluated in clinical trials treating 
small-cell lung cancer and B cells-related tumours.
82,87
 Therefore it was suggested that blocking 
PMCA4 might enhance the effectiveness of some anti-cancer therapies. 
 
A recent study by Grice et. al. has focussed on the connection between SPCA1 and different 
breast cancer subtypes. SPCA1 is found to be associated with basal-like breast cancers, which, as 
mentioned earlier, has the poorest prognosis with minimal therapeutic agents available.
88
 
Increased expression of insulin-like growth factor receptor (IGF1R) has been identified in this 
study, which has a strong involvement in cancer initiation, proliferation and resistance to anti-
cancer therapy. This finding provides a window of opportunity to place SPCA1 as a new 
therapeutic target for basal-like breast cancer. In another words, if SPCA1 is inhibited, will this 
reduce the IGF1R production that will ultimately inhibit basal-like breast cancer tumour growth? 
Therefore the aims of this research project are to fully understand the role of SPCA1 in basal-like 
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breast cancer and to design, synthesise and test chemical compounds that will inhibit the growth 
of basal-like breast cancer cells in vitro. 
 
1.4 Molecular modelling 
1.4.1 Grid-based ligand docking with energetics (Glide) 
The Glide program suite essentially searches for favourable interactions between a ligand and a 
macromolecular receptor, which is usually a protein molecule.
89
 It carries out this function based 
on using a hierarchical filter to evaluate the interactions between selected ligands and the target 
receptor.
90-92
  The filter tests the spatial fit of the ligand to the defined active binding site. Then it 
will assess the ligand-receptor interactions by using a grid-based method produced from an 
empirical ChemScore function.
93
 Ligand poses that have passed the initial screening will enter 
into the final stage of the hierarchy. 
 
 
 
 
 
 
 
Figure 7.  GLIDE generated receptor grid (shown as 
two boxes representing the grid boundary) 
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The first stage of the hierarchy filter is the Site-Point Search.
89
 This initially involves looking for 
all possible ligand locations in the active binding site. Each ligand molecule is divided into a 
core region and a number of rotamer groups due to being attached to its core via rotatable bonds. 
Each ligand molecule will have about 500 conformations generated based on the number of 
rotatable bonds, any 5- and 6- membered rings, any presence of long-range internal hydrogen 
bonds and asymmetric pyramidal trigonal nitrogen centres in the core. Then, during the docking 
process, every possible location and orientation will be searched over the entire active site of the 
protein for the generated ligand conformations. The active site or ligand binding site is 
represented by two boxes which will be referred to as “grid” from hereafter in the Site-Point 
Search.
89
 A 2Å grid represented by the purple box in Figure 7 is the volume in which the grid 
potentials are computed and where all the ligand atoms are located. The purple box is formed 
based on the distances from the site point to the receptor surface. These distances are evaluated 
by the programme at a series of pre-specified directions and then sorted into different distance 
ranges covering the active site region. A second 1Å grid, represented by the green box in Figure 
7, is then assigned based on the distances from ligand centre, which is the midpoint of the two 
most separated atoms, to the ligand surface. The green box represented the volume that the 
ligand centre explores during the Site-Point Search. Therefore, the whole Site-Point Search 
process runs from comparing the distance ranges from the site point to the receptor and the 
distance from the ligand centre to its surface (purple grid (box) versus green grid (box) as shown 
on Figure 7). The Glide programme will place the ligand centre at the site point for a good 
match within the Site-Point Search. 
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The second stage of the hierarchical filter is followed by Diameter Test which is to examine the 
atom placements within a specified distance of a line between the most separated atoms.
89
 This is 
also known as the ligand diameter. The ligand-receptor orientation will be skipped if there are 
any steric clashes present within the ligand diameter. The rotation of the ligand around the ligand 
diameter is also tested. To evaluate this property, a Greedy Scoring system 
93
 is set up based on 
Schrödinger’s own version of ChemScore empirical scoring function. Each subset of ligands or 
atoms that are capable of making hydrogen bonds or ligand-metal interactions with the receptor 
will be scored via this Greedy Scoring. Greedy Score also takes into account any favourable 
hydrophobic interactions, and unfavourable steric clashes and allows atoms to move ±1Å in x, y 
or z directions to compensate for large 2Å jump in the site point or ligand centre position. The 
top Greedy Scores will then be re-scored via a refinement procedure where the ligands are 
allowed to move rigidly by ±1Å in the Cartesian directions. 
 
Only about 100 to 400 ligand-receptor poses will reach the final Grid Minimisation stage. This 
stage mainly focuses on conducting energy minimisation on a set of van der Waals electrostatic 
grids which have been fine-tuned to reduce the large energy and gradient terms resulting from 
close inter-atomic interactions. Eventually, the energy-minimised poses will be re-scored again 
by using Glide score scoring function generated by Schrödinger.92 Glide (G) score is based on 
ChemScore as mentioned previously but also takes into account of steric-clash term, other 
rewards and penalties such as buried polar terms, amide twice penalties, hydrophobic enclosure 
terms and excluded volume penalties plus other modifications to other terms mentioned in the G 
score algorithm developed by Schrödinger (as shown below). The standard unit of G score was 
measured in kilocalories per mole (kcal/mol) (Equation 1). 
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G score = 0.05 x van der Waals interactions + 0.15 x Coulomb energy + Lipophilic term + 
Hydrogen bond + Metal-binding term + Rewards + Penalty for freezing rotatable bonds + 
Polar interactions in the active site (polar but non-hydrogen bonding atoms in a hydrophobic 
region are also rewarded) 
Equation 1. Schrödinger Glide Score 
 
1.4.2 Sitemap and receptor grid generation 
In the field of structure-based drug design, there are times when the actual drug binding site is 
not known or alternative binding sites are required in order to know any new biological effects of 
a drug. A specific in silico visual tool is needed in order for researchers to ascertain the probable 
drug interactions prior to the experimental stage. Numerous computational models have thus 
been derived to search for optimal drug binding sites.
94-107
 A variety of different methods such as 
using binding site geometry, structures, physiochemical properties, fragment probes and 
combining the electrostatic potential, binding surface curvature with the amino acid residues 
have also been assessed for identifying desirable binding sites. Surface Cavity REcognition and 
EvaluatioN (SCREEN) was developed and used to identify and characterise protein surface 
cavities.
108
 SCREEN is a surface segmentation method attempting to define and characterise 
cavities on a set of 99 proteins co-crystallised with drugs. The most decisive factors found to 
identify a druggable binding site were the shape and size of these surface cavities. 
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Schrödinger’s SiteMap is also a useful tool developed for identifying druggable sites on 
receptors.
109
 A systematic approach is employed throughout the binding site identification 
process. It begins with a search on the protein surface to determine if one or more regions could 
be the potential ligand binding sites.
110
 Site points are linked throughout this stage to mark the 
sites that have the greatest potential to provide tight protein-ligand or protein-protein binding. 
Second stage involves forming maps showing regions of hydrophobicity or hydrophilicity. The 
hydrophilic map would be further divided into donor, acceptor and metal-binding regions. 
Altogether there are six types of maps available via colour-coded mesh systems to enable users 
to identify the desirable active or druggable site (Figures 8). The hydrophobic region would be 
represented by yellow and hydrophilic map would be displayed in green. The hydrogen-bonding 
donor region would be coloured violet blue and hydrogen-bonding acceptor region in red. Metal-
binding map on the other hand would be in pink mesh form. The surface region was then shown 
in grey. The final stage involved evaluating all the energy property calculations at each site, 
which can then be inspected. 
 
 
 
 
 
 
 
Figure 8  A close-up view of druggable sites (colour-coded 
mesh system) on SPCA1d-1SU4 model 
 
34 
 
SiteMap has also confirmed size and relative openness of the binding sites as significant factors 
in site identification when compared with SCREEN.
111
 However, Sitemap has further developed 
a binding site predicting term, Site Score, to effectively distinguish sites that could bind ligands 
to sites that could not. Site Score was developed based on the number of site points involved in a 
binding site, degree of enclosure and hydrophilic scores for the site. The degree of site enclosure 
was measured based on the openness of the binding site. Typically a Site Score of 0.80 would aid 
in discriminating between a druggable and non-druggable site. Site Score of at least 1 and above 
indicated a reasonable chance for the site to be druggable. However, Site Score only aids in 
distinguishing a potential drug binding site and not showing the degree of druggability of the site. 
To address this, SiteMap has generated a similar scoring term, the Druggability Score (Dscore), 
to classify the druggability of the protein binding site to tightly bind passively absorbed small 
molecules. Dscore differs from Site Score where the hydrophilic score was not capped at 1 as in 
Site Score. This ensured Dscore would truly reflect a druggable binding site since it was found 
that difficult or undruggable binding site usually were more hydrophilic and less hydrophobic 
than the druggable sites.
105,111
 
 
1.4.3 Protein preparation 
Protein preparation is a crucial step to ensure the protein crystal structures for the homology 
models were refined adequately and correctly to optimise docking results. A few examples of 
structure-based virtual screening in drug discovery have used protein preparation wizard with 
some promising results.
112-114
 Protein preparation can be done via the Protein Preparation Wizard  
115
 or manually. It involved a series of steps to optimise hydrogen bonds, add any missing 
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hydrogen atoms and remove any steric clashes within the receptor model prior to the docking 
process.
116,117
 Other functions that Protein Preparation Wizard provided were to correct any 
metal ionisation state of the protein and remove water molecules if required.  
 
1.4.4 Glide scores and molecular mechanics generalised born surface area (MM-GBSA) 
methods 
Molecular dynamics have long been an interesting field for molecular modelling research 
involving biological macromolecules. Molecular dynamics research was separated into four 
different eras investigating the complex system of biological molecules in silico.
118
 The 
computer simulation in theory would largely reduce financial cost in conducting drug-discovery 
research and also to enable studies of the intricate biological systems. The first era began with 
the most primitive method of studying protein structure, where there were inadequate 
computational power to account for the surrounding environment of the biological 
macromolecules. This has evolved later to combine both free energy calculations from the 
second era and structure calculations from the third era into the final era plus what was already 
discovered from the first era to enable the understanding of macromolecular molecular dynamics.  
 
This then lead to two major solvation models developed to assist our understanding of molecular 
dynamics 
119
. Explicit solvent model initially focussed on treating solvent molecules at atomic 
levels which equally meant that it would use high computer power and cost to run modelling 
work. Then along came the Poisson-Boltzmann (PB) methods for implicit solvent model to 
calculate solvation free energies but it still required a significant amount of computer power. 
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Therefore a simpler implicit solvation model was developed and known as the generalised Born 
model which used less computational expense and reproduced similar promising results when 
compared to the PB methods 
120
.  
 
One of the studies comparing different methods for free energy prediction for protein-ligand 
complexes have shown that the molecular mechanics Poisson-Boltzmann surface area (MM-
PBSA) and MM-GBSA methods had the best correlation between the estimated and 
experimental values 
121
. Both of these methods have different strengths and weaknesses. MM-
PBSA was shown to be better at predicting absolute but not relative binding free energies than 
MM-GBSA 
122
. However, as mentioned before, due to MM-GBSA being more computationally 
efficient, it would be more useful in drug design.  
 
Essentially, the Prime MM-GBSA module within the Schrödinger programme suite was 
developed to predict the binding affinities and strain energies of the ligands to the target 
protein.
123
 The calculated values would not necessarily be the same as the experimental binding 
affinities but MM-GBSA would rank-order the ligands based on the calculated binding energies 
which is named MM-GBSA dG bind. The MM-GBSA dG bind is based on this equation from 
Schrödinger: DG bind = E_complex(minimised) - E_ligand(minimised) -E_receptor(minimised). 
The ligand strain energy can also be calculated from the difference between the calculated 
energy for the ligand extracted from the optimized complex (as if the ligand was optimised in the 
receptor binding pocket) and the calculated energy minimisation of the ligand outside the 
receptor. The ligand would be treated alone in solution for both calculations.  
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The Prime MM-GBSA module had originated from a surface-area-based version of the 
generalised Born (SGB) model.
124
 The SGB model had empirical correction scheme trialled to 
correct the energy prediction errors in order to be comparable to the PB results. This SGB model 
was further refined to take into account the hydrophobic term and variable dielectric constant to 
improve protein loop and side chain predictions in the homology models.
125,126
 The newer 
version of Prime MM-GBSA 2011 and later versions added the ability to assign the protonation 
state of the receptor model which improved long protein loop prediction of up to 20 residues.
127
 
There have been numerous different studies using MM-GBSA to explore the energetics and 
structure of nucleic acid, protein-protein interactions where, for example, the binding free 
energies of filamin A subunits with bound peptides were estimated and in lead optimisation and 
discovery projects involving protein kinase inhibitors.
128-131
 
 
1.5 Aims of the project 
The goal of this research project was to discover potential chemical compounds that could be 
further developed to become lead compounds to target SPCA1 and also SERCA pumps. The 
drug design process would need to be robust enough to ask the question; could a SERCA 
inhibitor be developed based on the drug design process involving molecular modelling, 
chemical synthesis and biological testing? If this first step was achieved then the next critical 
step was to design a SPCA1 inhibitor as SPCA1 was found to be highly involved in basal-like 
breast cancer. The potential lead compounds would then have the opportunity to become novel 
anti-cancer agents targeting basal-like breast cancer in this context. The ultimate aim was to 
38 
 
widen the current therapeutic agents available for patients with basal-like subtype of breast 
cancer in the hope to further improve their quality of life and life expectancy. 
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CHAPTER 2: METHODS 
 
2.1 in silico molecular modelling 
Structure-based drug design was the main technique adopted in this project. This technique 
involved modelling the target proteins, SERCA and SPCA, in their 3D forms and evaluating the 
binding affinities of potential ligand molecules to these protein targets. The Schrödinger suite of 
programs was used exclusively throughout the modelling process.
123,132
  
 
2.1.1 Software and software components used 
All software and software components were run on the Maestro interface from Schrödinger 
unless otherwise stated.  Comparative or homology modelling was carried out using Prime with 
two software components used, which were Protein Preparation Wizard and Structure Prediction 
Wizard. Ligand binding sites were found using SiteMap with Receptor Grid Generation used. 
Ligand preparation process used LigPrep. Ligand docking required Glide to carry out the 
docking process with details explained in section 2.1.4.2. Side-chain substitution on some of the 
ligands was trialled using CombiGlide with its embedded component BREED used. Details of 
the BREED component were further explained in section 3.1.4. The crystal structure of 
compound 16 was solved by using SHELXS refined by using SHELXL.
133
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2.1.2 Comparative or homology modelling 
2.1.2.1 SPCA 
The human protein sequence of SPCA was found from National Centre for Biotechnology 
Information (NCBI) Protein and its FASTA sequence was used as the protein template for the 
SPCA homology models.
123,134,135
 The most suitable SERCA homolog was selected based on at 
least 30% similar identities between the homolog and SPCA protein sequence (Table 1).  It was 
suggested that if the sequence identities were below 30%, the sequence alignment would fall into 
the twilight zone and become less accurate.
136
 The crystal structure resolution was at least less 
than 3Å for the SERCA homolog to increase the clarity and accuracy for the SPCA model 
(Table 1). Two comparative models were built for SPCA1d and SPCA2 (Appendix E). For the 
SPCA2 PDB ID model, the SERCA homolog used was PDB ID 1IW0 (chain A). SPCA1d model 
used 1SU4 (chain A). Once the SPCA homology models were constructed (Figures 9 and 10), 
their 3D protein structures were prepared via Protein Preparation Wizard under Prime.
115
 The 
preparation process included assigning bond orders, adding hydrogen atoms, adjusting bond 
orders and formal charges, enhancing hydrogen bonds, deleting crystallographic waters, 
eliminating atomic clashes via protein minimisation with the OPLS_2005 force field.
116,117
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2.1.2.2 SERCA 
Similar procedures were undertaken to build the homology models for all three SERCA isoforms. 
Each of the PDB-derived protein crystal structures were selected from BLAST Homology Search 
under the Structure Prediction Wizard.
123
 The SERCA homologues selected were based on the 
criteria mentioned previously for SPCA homology models (Table 1). Sequence alignments of 
each homology model were available in Appendix E. 
 
 
 
 
Figure 9  Homology model of SPCA2-1IW0 Figure 10  Homology model of SPCA1d-1SU4 
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Ca
2+
 
ATPase 
isoforms 
PDB ID Name Identities Positives Source Experiment Resolution 
SPCA1d 1SU4 Chain A of 
crystal 
structure of 
Ca
2+-
 
ATPase 
with two 
bound Ca
2+
 
32% 51% Oryctolagus 
cuniculus 
X-ray 
diffraction 
2.4 Å 
SPCA2 1IW0 
 
Chain A of 
the SR 
Ca
2+
-
ATPase in 
the absence 
of Ca
2+
 
32% 50% Oryctolagus 
cuniculus 
X-ray 
diffraction 
3.1 Å  
SERCA1 3AR5 Chain A of 
Ca
2+
 pump 
crystal 
structure 
with bound 
TNP-AMP 
and TG 
96% 98% Oryctolagus 
cuniculus 
X-ray 
diffraction 
2.2 Å 
SERCA 2 3AR4 Chain A of 
Ca
2+
 pump 
crystal 
structure 
with bound 
ATP and 
TG in the 
absence of 
Ca
2+ 
84% 93% Oryctolagus 
cuniculus 
X-ray 
diffraction 
2.15 Å 
SERCA 3 3AR7 Chain A of 
Ca
2+
 pump 
crystal 
structure 
with bound 
TNP-ATP 
and TG in 
the absence 
of Ca
2+
 
75% 88% Oryctolagus 
cuniculus 
X-ray 
diffraction 
2.15 Å 
 
Table 1 Details and statistics for all SPCA & SERCA homology models. Identities % corresponds 
to the percentage of residues that are identical between the sequences. Positives % is the percentage 
of residues that are positive matches according to the similarity matrix selected – default setting 
uses BLOSUM62 matrix. 
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2.1.3 Identifying ligand binding sites  
SiteMap was used for identifying ligand binding sites for SPCA1d model under default settings. 
The only change made was 6 sites were chosen for the reporting of site-point groups by SiteMap 
instead of the default setting of 5 sites. This was done to increase the chance of finding more 
ligand binding sites, which were named as site-point groups in the SiteMap software component. 
Ligand binding sites could be set up via Receptor Grid Generation. All the grids generated in this 
project used the default setting. Grids were shown in Figure 9 with both larger purple and 
smaller green 3D grids. Each grid represented the binding site for the ligand sets.  
 
Additionally, other methods used to identify ligand binding sites on the receptor models was by 
compiling a Venn diagram of all the amino acid residues present within the ligand binding sites 
(Figure 11). Initially, the library of TimTec ligands 
137
 was docked on the SPCA2 model on the 
original TG binding site. The decision of using TimTec library was due to previous experience in 
the drug design area in our lab group. Then all the amino acid residues present within the ligand 
binding site were recorded for each docked ligand. The amino acid residues that have recurred 
most often for all the ligands docked were used to set up the trial grids. The numbered positions 
of at least three amino acid residues within the receptor were used to set up a receptor grid. Each 
specific position of the amino acid residue was represented by three digits after the shorthand of 
the amino acid name (Figure 11).  The three amino acid residues were randomly chosen from 
the six most common amino acid residues from the Venn diagram to assist with the setting of 
ligand binding sites (grids). 
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2.1.4 Docking of ligands 
The ligands used in this project were obtained from ZINC, a free database of 13 million 
commercially-available compounds, readily accessible by academic or pharmaceutical 
researchers involved in structural-based virtual screening research.
137
 Ligands were downloaded 
as SDF files from the TimTec sub-database from ZINC, in reference pH of 7. The downloaded 
ligands were separated in sets of five with a total number of 271,965 used for high throughput 
virtual screening for both SERCA and SPCA models (set 1: 136,987 structures, set 2: 90,629 
structures, set 3: 17,692 structures, set 4: 10,325 structures and set 5: 16,332 structures).  
 
Figure 11  Venn diagram used for identifying common amino acid residues 
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2.1.4.1 Ligand preparation 
Schrödinger’s LigPrep was used to ensure the desired ligand was in a low-energy state with 
correct stereochemistry for its structure.
138
 The importance of stereochemistry in virtual 
screening was emphasised by Brooks et. al. where inclusion of all stereoisomers of all potential 
lead compounds was crucial to minimise any false negatives or to prevent losing a significant 
proportion of the potential leads.
139
 LigPrep can also convert a 2D drawn structure to its 3D form 
which would be further processed via a series of steps to prepare the 3D ligand. The preparatory 
steps involved ensuring the ligands existed in appropriate ionisation states, tautomers, ring 
conformations, molecular weights and also the number and types of functional groups. 
 
Numerous studies using structure-based virtual screening to search for potential lead compounds 
targeting specific diseases have used LigPrep.
131,140-143
 LigPrep was also used to prepare in silico 
enzyme inhibitors during a molecular docking study targeting a multifunctional kinase involved 
in a wide range of diseases.
144
 Other studies have used LigPrep to find novel biosynthetic 
pathways for fuels such as 1-butanol, to build a 3D-quantitative structure-activity relationship 
model to predict the activity of desired candidate compound prior to synthesis and also for 
understanding the binding modes and activities of bromobenzimidazole casein kinase 2 
inhibitors.
145-147
  
 
Non-TimTec ligands used were prepared by using LigPrep prior to all docking protocols.
138
 All 
other TimTec ligands were also prepared by LigPrep prior to the docking process. 
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2.1.4.2  Ligand docking on SPCA models 
All TimTec ligands downloaded from ZINC were subjected directly to high throughput virtual 
screening (HTVS) docking initially, followed by standard precision (SP) and then extra precision 
(XP) docking.
89
 These three docking modes were applied to all docking carried out in this project 
in this order. HTVS docking was the first docking mode used to reduce the number of 
intermediate conformations throughout the docking funnel. The SP mode was used to screen the 
ligands with reasonable HTVS Glide scores as chosen by the user. XP mode was designed for 
use on top-scoring ligand poses to screen false positives and active compounds that could bind to 
a specific conformation of the receptor. Each docking job of the selected ligands was processed 
and separated into a number of subjobs to be run by a limited number of central processing units 
(CPUs) in the computer, restricted by the number of Glide licences present. 
 
To validate the method, ligand docking was first trialled on TG-binding site to the SPCA2-1IW0 
model. This was done by using Glide via the Maestro interface.
89-92,132
 Prior to the ligand 
docking, TG was prepared by using LigPrep. Six prepared TG conformers generated from 
LigPrep were docked onto the SPCA2-1IW0 homology model. This step was done to assist in 
finding the six TG-binding sites which would then be trialled for subsequent ligand docking. The 
Glide docking process was then started with Set 1 of the TimTec ligands as mentioned before. In 
order to filter out the desirable ligands for the target receptor, the Glide docking process was 
carried out in the three docking modes in the order as mentioned previously.  
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After the docking process was completed for SPCA2-1IW0 model and the Venn diagram 
compiled, a tentative binding site was formed firstly for the SPCA1d-1SU4 model. The receptor 
grid, site 1, was set on LEU765, LEU256 and ILE834 which was originally based on the TG-
binding site. All five sets of TimTec ligands were docked on this same site. Following on, four 
more receptor grids were set up where all five sets of TimTec ligands were docked in the three 
docking modes. Site 2 grid was set on ILE769, PHE262 and PHE854. Site 3 was based on 
VAL761, VAL274 and ILE828. For site 4, the grid was selected on LEU260, LEU765 and 
ILE769. Last grid, site 5, was generated on LEU260, LEU765 and ILE837. Once all of the five 
ligand binding sites were trialled for docking, SiteMap was used to generate better ligand 
binding sites. Altogether three SiteMap sites for SPCA1d-1SU4 were discovered, selected and 
produced via using Receptor Grid Generation. SiteMap site 4 was selected based on the location 
of ALA142, LEU141 and PHE236. SiteMap site 1 was on LEU319, GLY322 and LYS251. 
SiteMap site 3 was on ASN756, GLY808 and SER252.  
 
2.1.4.3 Ligand docking on SERCA models 
All three SERCA models were subjected to Glide docking. The same grid-setting protocol was 
followed with SERCA as that for the SPCA models for the ease of post-docking comparison. 
SiteMap site 4 for SERCA1-3AR5 was set exactly the same as that for SPCA1d-1SU4 model 
(ALA142, LYS141 and ARG236). SiteMap site 1 for SERCA1-3AR5 was also the same as that 
for the SPCA1d-1SU4 model (LEU319, GLY322 and GLN251). SiteMap site 3 for SERCA1-
3AR5 was also the same (ASN756, GLY808 and LYS252). A TG-equivalent binding site was 
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also set up on ILE765, PHE256 and PHE834, according to the Venn diagram produced for 
SPCA2-1IW0 model. XP docking was then started for the same 26 ligands on these four set grids. 
 
For SERCA2-3AR4 model, four equivalent receptor grids were set up as for the SERCA1-3AR5 
model. SiteMap site 4 was on ALA142, LYS141 and ARG236. SiteMap site 1 had LEU319, 
GLY322 and GLN251. SiteMap site 3 was set on ASN756, GLY808 and LYS252. Lastly for the 
TG-equivalent binding site, this was generated on ILE765, PHE256 and PHE834. For SERCA3-
3AR7 model, the SiteMap site 4 was placed on ALA142, ARG141 and ARG236. For SiteMap 
site 1, this was located on LEU319, GLY322 and ARG251 and for SiteMap site 3, this was on 
ASN756, GLY808 and LYS252. The TG-binding site was lastly set on ILE765, PHE256 and 
PHE834. Same XP docking for the same group of 26 ligands were done for these eight grids for 
both the SERCA2-3AR4 and SERCA3-3AR7 models. 
 
2.1.5 CombiGlide trial 
Side-chain substitutions were also trialled on the six compounds selected preliminarily via 
CombiGlide to see if better hit generation could be obtained prior to biological testing.
148
 The 
side-chain substituents were taken from the Schrödinger website, where a total of 665 fragments 
were downloaded and separated into three combinatorial libraries to enable efficient docking 
processes. XP docking mode was used throughout the fragment docking for all six selected 
compounds. Interactive enumeration and docking function was used within CombiGlide. The 
point of side-chain substitution on the six selected compound structures was manually selected to 
indicate where the fragment would be attached (Figure 12). 
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Figure 12 Six structures showing the site of side-chain substitutions. Red arrows indicate the broken 
bonds with new fragment attached. (ZINC08846492 and ZINC08846618 for SPCA1d-1SU4, 
ZINC09089406 and ZINC66088673 for SPCA2-1IW0, ZINC04189857 for SERCA1-3AR5 and 
SERCA2-3AR4 and ZINC32216656 for SERCA3-3AR7) 
50 
 
2.2 Compound availability 
After completing all the docking and MM-GBSA analysis of the binding energies of the ligands, 
there were two options to obtain the target compounds. The compounds would either be 
synthesised in a chemistry laboratory or purchased from a suitable chemical supplying vendors if 
the stereochemistry of the target compounds were too complex to obtain a stable stereoisomer 
from laboratory synthesis. In the first round of structure-based virtual screening process, it was 
decided to purchase two compounds from TimTec due to complex stereochemistry of the 
selected compounds. 
 
2.3 Bioassay – intracellular calcium measurement 
2.3.1 MDA-MB-231 cell culture 
The selected compounds were tested in MDA-MB-231 breast cancer cell line to observe the 
effect on the intracellular Ca
2+
 level. The cells were initially thawed after removal from liquid 
nitrogen store. The thawed cells were then transferred to a new falcon tube with 9mL of 
Dulbecco’s Modified Eagle Medium (DMEM) added. The tube was then centrifuged to aid the 
removal of supernatant which would normally contain dimethyl sulfoxide (DMSO), the 
cryoprotectant agent.  The cells would then be resuspended in 1mL of DMEM. The cell 
suspension was then transferred to a culture flask containing the DMEM and mixed thoroughly. 
The culture flask was stored in the incubator at 37°C with 5% carbon dioxide (CO2) and 
observed for any contamination after 24 hours. 
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Cell feeding was carried out by replacing old media with fresh DMEM each time when the 
desired cell confluency was not reached. Cell splitting was carried out once every two to three 
days using trypsin after phosphate buffered saline (PBS)/ethylenediaminetetraacetic acid (EDTA) 
was added and separated into different flask for cell culture. The passage number and dilution 
factor were recorded after each cell splitting. Cells were plated when the cell growth was 
confluent with evenly-spread cells in the culture flask. Cell count was done to record the number 
of cells plated in each well. The final plate had about 15,000 cells in each well on a 96-well plate 
incubated at 37°C for 48 hours prior to running fluorometric imaging plate reader (FLIPR). 
Detailed cell culture methods were provided in Appendix B. 
 
2.3.2 Fluorometric imaging plate reader (FLIPR) 
 
The main instrument used for testing the Ca
2+
 signalling response in the MDA-MB-231 cell line 
was FLIPR
®TETRA
 High Throughput Cellular Screening System from Molecular Devices, LLC. It 
was intended to work as a high throughput optical screening tool for cell-based fluorescent 
assays.
149,150
 One of the major features of this instrument was the presence of simultaneous 
pipetting and reading capabilities to allow for rapid kinetic cellular assays. The number of pipette 
heads used in the experiment was 96 which could be increased to 382 or 1536 for other high 
throughput assays.  
 
The machine of FLIPR consisted of three main parts (Figure 13). The optical detection of FLIPR 
used the cooled charge coupled device (CCD) technology, in which the CCD camera would take 
a picture of the bottom of the plate to record signals for each individual cell concurrently. The 
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signal would be derived from the emitted light coming from the fluorescent indicator dye, fluo-4 
AM, which was excited by argon laser. During the running process, the FLIPR robot could 
aspirate the reagents from each of the two different fluid-addition plates and dispense them into 
the third one containing the cultured cells. The Ca
2+
 response outcomes within the cells could 
then be accessed from the software, FLIPR
®TETRA
 system, operated on ScreenWorks
®
 from 
Molecular Devices.  
 
 
 
 
 
 
 
Figure 13  Main components of a FLIPR system (taken from ref. 139)  
 
Prior to running FLIPR, two buffer solutions had to be made up. The first buffer solution was the 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) stock buffer that would maintain 
the pH of the solution. PSS buffer solution was the second buffer needed throughout the plating 
and preparation process for the similar purpose. The components within each buffer solution are 
given in Appendix C. 
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The FLIPR process was undertaken over two days (details in Appendix C). Day one involved 
plating cells in the 96-well plate in complete growth media. Day two involved preparing all three 
reagent plates and running the FLIPR assay. First reagent plate would have BAPTA added to 
each well. The second reagent plate would contain BAPTA, CPA, compounds 8 and 3 and 
DMSO. The third reagent plate would have Ca
2+
, BAPTA, DMSO, both compounds 8 and 3 
added to separate wells on the plate. FLIPR robot would then add the reagents from plate one, 
plate two then plate three to the cell plate in this order. 
 
2.3.2.1 Dose-response measurement 
Dose-response measurement was carried out after the completion of FLIPR to ascertain the 
biological activity of the tested compounds. Dose-response graphs were constructed using XY 
table and dose vs. response graphs from GraphPad Prism version 5 for Windows, GraphPad 
Software, La Jolla California USA. Error bars shown on the dose-response curves were 
automatically generated by GraphPad Prism by using mean and error plot with standard error of 
the mean. 
 
2.4 Chemical synthesis 
2.4.1 Molecular docking of compounds with pyrrolidone core 
Further molecular docking were performed after the results from the first two selected 
compounds were finalised from the FLIPR assay. The aim of the docking was to search for 
compounds with a pyrrolidone core from SciFinder, ZINC databases and PubChem. This 
pyrrolidone core 9 was identified after comparing the structure of Compound 3 (ZINC08846492 
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in Figure 12) with CPA 1 where both have similar structural motifs, incorporating a five-
membered pyrrolidone ring incorporating two carbonyl groups and an acetyl group.
151
 Therefore, 
this particular core structure might confer some structural-activity effect towards the design of a 
SERCA inhibitor. 
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One compound, 1-(2,4-dihydroxy-3-methylphenyl)-2-phenylethanone 10 was synthesised within 
our lab group by J. Hanh/H. Gao following literature methods.
152
 Because of the possibility of 
keto-enol tautomerism within this structure, it was decided to add this compound to the 
biological assay as this keto-enol tautomerism theme was common to this structure, CPA and the 
desired pyrrolidone-like core structure, despite other differences in their ring structures. The 
structure of diarylethanone 10 was confirmed by both 
1
H and 
13
C NMR spectroscopy, and the 
spectra correlated with the literature data.
152
  
Scheme 1 
 
The diallyl bisphenol A 13, Scheme 1, was considered when its structural activity relationships 
were investigated and found to increase the intracellular calcium levels in the human skin 
fibroblast cells, a phenomenon consistent to a SERCA inhibitor.
153
 This compound was 
synthesised from bisphenol A 11 via its allyl ether 12 derivative using published methods.
154
 
However, due to the hydrophobic properties of this compound, as a result of the allyl groups 
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attached on both aromatic rings, it was not ideally soluble in DMSO or aqueous media for testing 
in FLIPR. It was therefore decided to synthesise more water-soluble derivatives of diallyl 
bisphenol A; diallyl bisphenol A sulphate 14 and acetic acid 15 derivatives. Preparation of 14 
applying a modified literature method 
155
 was not successful. Synthesis of 3,3ʹ-diallyl-O,Oʹ-
bis(carboxymethyl)bisphenol A 15 was carried out using bromoacetic acid, scheme 2. 
 
 
 
 
 
 
 
Scheme 2 
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Based on the known anticancer effect of curcumin and also the link between SPCA and basal-
like breast cancer,
156
 curcumin 16 was synthesised using the established procedure 
157
 reacting 2 
equivalent of 4-hydroxy-3-methoxy-benzaldehyde with 1 equimolar of acetylacetone in the 
presence of boron oxide, as detailed in the Experimental Section, Scheme 3. The crystals were 
analysed and confirmed via X-ray diffraction and also 
1
H and 
13
C NMR which had correlated 
with literature data.
158
 
 
 
 
 
 
 
 
Scheme 3 
 
As pyrazole derivative 17 showed greater inhibitory potential on calcium/calmodulin dependent 
protein kinase II, it was considered as a suitable candidate to be subjected to biological testing. 
Heterocyclic analogue 17 was prepared by the published microwave assisted method 
157
 using 
the synthesised curcumin 16 and hydrazine, Scheme 4. 
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Scheme 4 
 
2.4.2 Experimental section 
2.4.2.1 Preparation of 1-(2,4-dihydroxy-3-methylphenyl)-2-phenylethanone 10 
1-(2,4-Dihydroxy-3-methylphenyl)-2-phenylethanone 10 was prepared by a literature procedure 
152
; (3.3 g, 54 %); 
1
H NMR (400 MHz, CDCl3) δH 2.11 (3H, s, CH3), 4.20 (2H, s, CH2), 5.59 (1H, 
broad, OH), 6.34 (1H, d, J = 8.8 Hz, H-5ʹ), 7.23-7.26 (3H, m, Ar-H), 7.30-7.34 (2H, m, Ar-H), 
7.61 (1H, d, J = 8.8 Hz, H-6ʹ), 12.96 (1H, s, OH); 13C NMR (75 MHz, CDCl3) δC 7.2 (CH3), 
44.7 (CH2), 106.9 (CAr), 111.2 (CAr), 112.9 (CAr), 126.9 (CAr), 128.6 (CAr), 129.2 (CAr), 129.4 
(CAr), 134.4 (CAr), 160.2 (CAr), 163.4 (CAr), 202.1 (C=O, quat.). 
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2.4.2.2  Preparation of diallyl bisphenol A 13  
2.4.2.2.1 Preparation of diallyl ether of bisphenol A 12 154 
Bisphenol A 11 (2.968 g, 13 mmol), allyl bromide (4.718 g, 38.99 mmol), and potassium 
carbonate (5.5 g) were dissolved in acetone (30 mL) and refluxed overnight, under nitrogen. The 
reaction was monitored by thin layer chromatography (TLC). The solution was then cooled, 
filtered and the solvent evaporated under reduced pressure. The residue was dissolved in DCM 
(50 mL) and washed with dilute aq. sodium carbonate solution (2 × 25 mL) followed by water 
(25 mL). The remaining organic layer was dried over anhydrous sodium sulphate, filtered and 
evaporated under reduced pressure to give bisphenol A diallyl ether 12 a yellow-brown oil (2.49 
g, 84 %); 
1
H NMR (400 MHz, CDCl3) δH 1.62 (6H, s, 2 × CH3), 4.48 (4H, d, J = 6.4 Hz, 2 × 
CH2), 5.24-5.27 (4H, m, 2 × CH2=), 5.37 (1H, s, OH), 5.99-6.07 (2H, m, 2 × CH=), 6.80 (4H, m, 
Ar-H, H3, H5), 7.11 (4H, m, Ar-H, H2, H6). 
 
2.4.2.2.2 Rearrangement of ether 12 to 3,3ʹ-diallyl bisphenol A 13 154 
The diallyl ether of bisphenol A 12 (2.49 g, 8.07 mmol) was dissolved in DCM (24 mL). The 
reaction was carried out on an ice bath containing a mixture of ice, acetone and sodium chloride 
(-10 °C). Boron trichloride (12 mL; 1M solution in DCM; 12 mmol) was carefully added and 
stirring was continued for 4 hours at -10 °C. The reaction was monitored by TLC and after it was 
complete, water (30 mL) was added and the mixture was stirred for a further 15 minutes. The 
DCM layer was then separated and washed with water (3 × 50 mL) then dried over anhydrous 
sodium sulphate, filtered and evaporated under reduced pressure to give 3,3ʹ-diallylbisphenol A 
13 as a brown oily liquid (1.87 g, 6.06 mmol, 75 %); 
1
H NMR (400 MHz, CDCl3) δH 1.63 (6H, s, 
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2 × CH3), 3.38 (4H, d, J = 6.4 Hz, 2 × CH2), 5.12-5.17 (4H, m, 2 × CH2=), 5.30 (1H, s, OH), 
5.96-6.06 (2H, m, 2 × CH=), 6.71 (2H, d, J = 8.8 Hz, H-5,5ʹ), 6.96-6.99 (4H, m, Ar-H).  
 
 
2.4.2.3 Preparation of 3,3ʹ-diallyl-o,oʹ-bis(carboxymethyl)bisphenol A  15 159 
3,3ʹ-Diallylbisphenol A 13 (1.87 g, 6.07 mmol) in THF (100 mL) was added to sodium hydride 
(0.87 g; 60% dispersion in mineral oil, 36.40 mmol) in dry DMF (25 mL) and the solution was 
stirred for 30 minutes at ambient temperature. Bromoacetic acid (2.01 g, 14.60 mmol) was added 
and the mixture was heated at 60°C under reflux, overnight. The solution was allowed to cool 
then 1M aq. HCl was added dropwise until a pH of 2 was obtained. The aqueous layer was 
extracted with ethyl acetate (3 × 40 mL). The collected organic layers were dried over Na2SO4 
and the solvent was evaporated yielding a brown oil which was then triturated with petroleum 
ether to give 15 as a whitish-yellow solid (13.168 g, 100 %, 146 - 148°C ); 
1
H NMR (400 MHz, 
DMSO-d6) δH 1.51 (6H, s, 2 × CH3), 3.29 (4H, d, J = 6.4 Hz, 2 × CH2), 4.60 (4H, s, 2 × 
OCH2COOH), 4.94 (4H, m, 2 × CH2=), 5.89 (2H, m, 2 × CH=), 6.69 (2H, d, J = 9.2 Hz, H-5,5ʹ), 
6.92-6.94 (4H, m, 4 × Ar-H), 12.91 (2H, m, 2 × COOH). 
13
C NMR (75 MHz, DMSO-d6) δC 31.2 
(CH3), 34.5 (CH2-CH=), 41.6 (CH3), 65.2 (O-CH2COOH), 111.4 (CH=CH2), 115.8 (CH=CH2), 
125.5 (CAr-5 or 6), 127.6 (CAr-2), 128.3 (CAr-5 or 6), 137.4 (CAr-3), 143.2 (CAr-1), 153.6 (CAr-4), 
170.8 (O-CH2COOH);  IR (Nujol) νmax/cm
-1
 1746 (COOH), 1246 (C-O), 913 (C-HAr); HRMS  
(ESI) Found: MNa
+
, 447.1779. Calc. for C25H28O6Na: MNa
+
, 447.1784.  
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2.4.2.4  Preparation of (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-
1,4,6-trien-3-one 16  
157
 
Vanillin (304.3 g), acetyl acetone (100.13 g) and boron oxide (200 mg) was dissolved in DMF (1 
mL). The reaction mixture was subjected to microwave irradiation at 55-60°C for 5 minutes. 
Acetic acid (60 µL) and n-butyl amine (50 µL) was added to the reaction vessel followed by 
repeated microwave irradiation for another 5 minutes. The resulting mixture was poured on 20% 
acetic acid in water (50 mL). The precipitate formed was filtered and recrystallised from ethanol 
to give 16 as red crystals (0.68 g, 100 %, 178 - 180°C) 
1
H NMR (400 MHz, DMSO-d6) δH 3.80 
(6H, s, 2 × OCH3), 6.02 (1H, s, CH=), 6.72 (2H, d, J = 16.0 Hz, 2 × CH=), 6.78 (2H, d, J = 8.0 
Hz, CHAr, H-5), 7.11 (2H, dd, J = 8.0 and 1.6 Hz, 2 × CHAr, H-6), 7.28 (2H, d, J = 1.6 Hz, 2 × 
CHAr, H-2), 7.51 (2H, d, J = 15.6 Hz, CH=); 
13
C NMR (75 MHz, DMSO-d6) δC 56.5 (CH3), 
101.3, 111.7, 116.1, 121.5, 123.6, 126.7, 141.1, 148.4, 149.8, 183.6 (C=O); IR (Nujol) νmax/cm
-1
 
1620 (C=O), 1600 – 1550 (C=C), 1283-1153 (C-O), 1026(C-HAr). 
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Figure 14  An X-ray refinement and Oak Ridge Thermal Ellipsoid Plot (ORTEP 
160
) drawing for 
compound 16 (ellipsoids are at the 30% probability level) 
 
 
2.4.2.4.1  X-ray data collection and reduction 
The single-crystal X-ray diffraction experiments were carried out at the University of Sydney 
using a Bruker APEX2 CCD-based diffractometer with an X-ray wavelength of 0.7107Å (Mo 
Kα) and at an experimental temperature of 150 K. The red single crystal of 16 (0.25 × 0.15 × 
0.15  mm) was mounted on the tip of a thin glass fibre with a minimum amount of Paratone N oil 
and inserted in the cold N2 stream of an Oxford Cryosystem COBRA instrument. X-ray 
diffraction data were collected using 0.3° ∆ω scans, maintaining the crystal-to-detector distance 
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at 6.01 cm. The diffraction data were integrated using SAINT+,
161
 and the unit cell parameters 
for 16 at 150 K were refined from 500 reflections in the monoclinic space group P21/n with Z = 4, 
F(000) = 776, and µ = 0.101 mm
-1
 (Table 2).  
 
Table 2  Independent Atom Model (IAM) Refinement of compound 16 
Empirical formula  C21H20O6  
Molecular mass  368.37  
Crystal size/mm
3
  0.25 × 0.15 × 0.15  
Temperature/K  150 
Crystal system  monoclinic  
Space group  P21/n  
a (Å)  12.614  
b (Å)  7.086  
c (Å)  20.009  
α (°)  90.00  
β (°)  94.83  
γ (°)  90.00  
Volume (Å
3
)  1782.1  
Z  4  
ρcalcmg/mm
3
  1.373  
µ/mm
-1
  0.101  
F(000)  776.0  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection  3.68 to 42.5°  
Index ranges  -12 ≤ h ≤ 12, -7 ≤ k ≤ 6, -20 ≤ l ≤ 20  
Reflections collected  7628  
Independent reflections  1974[R(int) = 0.0646]  
Data/restraints/parameters  1974/0/257  
Goodness-of-fit on F
2
  1.009  
Final R indexes [I>=2σ (I)]  R1 = 0.0420, wR2 = 0.0931  
Final R indexes [all data]  R1 = 0.0816, wR2 = 0.1112  
Largest diff. peak/hole / e Å
-3
  0.21/-0.18  
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The structure of 16 was solved using direct method SHELXL-97,
133
 and full-matrix least-squares 
refinement on F
2
 was carried out using SHELXL-97. All non-hydrogen atoms were refined 
anisotropically. Hydrogen atoms were included in idealised position, with U150 tied to 1.5 times 
that of the parent atom. An ORTEP drawing of compound 16 could be seen in Figure 14. Given 
the low values of R1 and wR2 , we could conclude that this was a structure of reasonable quality. 
 
2.4.2.5 Preparation of 3,5-bis{2ʹ-(4-hydroxy-3-methoxyphenyl)-(1ʹE)-ethen-1ʹ-yl}1H-
pyrazole 17 
157
 
Curcumin 16 (0.3 g), acetic acid (1 mL) and hydrazine hydrate (80 µL) was dissolved in DMF (1 
mL) and subjected to microwave irradiation at 55-65 °C for 5 minutes. After addition of 
hydrazine hydrate (80 µL) the irradiation cycle was repeated. The resulting mixture was poured 
into water (40 mL) and the solid formed upon standing was filtered to give crude product 17, 
which was then purified by gradient column chromatography (ethyl acetate-hexane 1-1 to 9-1) to 
yield an off-yellow solid 17 (0.16 g, 53 %, 217 - 219°C); 
1
H NMR (400 MHz, DMSO-d6) δH 
3.79 (6H, s, 2 × CH3), 6.59 (1H, s, CH, H-4l), 6.74 (2H, d, J = 8.0 Hz, 2 × CHAr, H-5), 6.87-6.91 
(4H, m, 2 × CHAr and 2 × CH=), 7.01 (2H, d, J = 16.8 Hz, 2 × CH=), 7.11 (2H, s, 2 × CHAr, H-2), 
9.14 (1H, broad, OH), 12.8 (1H, broad, OH); 
13
C NMR (75 MHz, acetone-d6) δC 55.3 (CH3), 
99.1 (C=Cpyrazole), 108.9 (CAr-2), 115.1(CAr-5), 120.3 (C=C), 129.2 (C=C), 129.8 (CAr-6), 146.8 
(CAr-3 or 4 or C=N), 147.7 (CAr-3 or 4 or C=N); IR (Nujol) νmax/cm
-1
 3478(OHphenol), 3314(N-H), 
1594(C=N), 1280(C-O); HRMS  (ESI) Found: MH
+
, 365.1000. Calc. for C21H21N2O6: MH
+
, 
365.1501. 
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CHAPTER 3: RESULTS AND DISCUSSION 
 
3.1 Molecular modelling results 
3.1.1 SPCA 
3.1.1.1 SPCA2 
As mentioned earlier in section 2.1.4, there were a total of five sets of TimTec ligands 
downloaded for docking. Set 1 contained 136,987 TimTec ligand structures, set 2 had 90,629 
TimTec structures, set 3 had 17,692 structures, set 4 had 10,325 structures and lastly set 5 had 
16,332 structures. HTVS docking mode was used as the first docking step and was repeated three 
times in total for set 1 and 2 TimTec ligands. Each time the subjob number was reduced for 
docking to see if this would increase the number of ligands with G scores of -7 or below. TimTec 
ligands from set 3, 4 and 5 were repeated twice in the three docking modes for the same purpose 
of increasing the number of hits for virtual screening. The binding site for all the TimTec ligands 
from all dockings methods was based on the TG binding site. 
 
Altogether there were two important criteria used in this project for choosing compounds with 
the highest potential for biological activity. G scores were one of the factors and the other 
component was the results from MM-GBSA. G scores were a useful indicator of how well the 
compounds have performed in the in silico docking based on a rank-scoring system as mentioned 
previously. According to Schrӧdinger, G scores around -8 and -9 kcal/mol were considered to be 
very good for shallow binding sites or sites with mainly hydrophobic interactions.
89
 For Glide 
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XP mode docking, G scores were usually -12 kcal/mol or below. For Glide HTVS or SP mode 
docking, G scores of -10 kcal/mol or lower usually indicated good binding of the ligand. 
 
Docking for set 1 ligands was initially run by 16 subjobs in the HTVS mode.  The result from 
this gave 49 ligands with G scores of at least -8 or below. For the second round, 8 subjobs were 
used to run the HTVS mode docking for the same set 1 ligands at the same site and this provided 
66 ligands with G scores of at least -8 or below. For the third round of HTVS docking, 6 subjobs 
were used and this produced 140 ligands with G scores of at least -8 or below. The number of 
subjobs was reduced from 16 to 8 then lastly to 6 for each round. This applied to all the 
subsequent docking mentioned hereafter unless otherwise stated. The HTVS docking results for 
set 1, 2, 3, 4 and 5 ligands were shown in Table 3. 
 
 Number of Tim Tec ligands with G scores of at least -8 or less 
HTVS docking mode Set 1 Set 2 Set 3 Set 4 Set 5 
16 subjobs used 49 54 N/A N/A N/A 
8 subjobs used 66 74 30 3 38 
6 subjobs used 140 100 56 4 77 
Table 3 HTVS docking mode results for Tim Tec ligands on SPCA2 model 
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The set 1 ligand SP docking has produced a total of 131 ligands with G scores of at least -8 or 
below by using 8 subjobs. For set 2 ligands, this has produced 219 ligands of G scores of about -
8 or below.  For set 3, the top 300 ligands with G scores of about -8 or below were chosen to run 
the XP mode docking. This has lead to a total of 19 ligands with top G scores of at least -10 to 
about -11.6. Set 4 SP docking has given 100 ligands with G scores from about -7.7 to -8.9. These 
ligands were subjected to XP docking and produced two ligands with G scores of about -10.3. 
From SP docking for set 5 ligands, this has generated a total of 400 ligands with G scores of 
about -8 to -10.6. XP docking was then performed for these ligands and found a total of 11 
ligands with G scores of -10 to -11.5. All the ligands generated from XP mode dockings from set 
1 to 5 were saved in separate SDF files and 2-dimensional (2D) viewer PDF files. 
 
The 131 ligands from set 1 SP docking has been trialled for XP docking but only generated two 
ligands with G scores of about -10.7 to -10.8. Therefore, the SP docking was repeated and the 
number of subjobs used to run the SP docking was reduced from 8 to 6 to see if this would 
provide better result. This gave altogether 100 ligands with G scores of about -8 to -9.8 from the 
SP docking. These ligands were then subjected to the XP docking, which produced 5 ligands 
with G scores of about -10 to -11. The SP docking was also repeated for set 2 ligands with the 
subjob number reduced from 8 to 6. The 100 ligands from the HTVS docking for set 2 were put 
through the SP docking mode. The result of this has provided 90 ligands with G scores of about -
7.4 to -9.3. These ligands were sent through to XP docking and finally produced 3 ligands with G 
scores of about -10.2 for two of the ligands and the last one had about -10.9. 
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From the docking results of the Tim Tec ligands (set 1 to 5) on SPCA2-1IW0 model, there were 
altogether 40 ligands that had XP G scores of around -10. A Venn diagram was compiled to 
show all the amino acid residues involved at the ligand binding sites from the dockings 
completed previously. Six amino acid residues, ILE765, VAL769, PHE256, VAL263, PHE834 
and ILE829, were discovered to be the most common amino acid residues for all 40 ligands. The 
grid was re-set by using three of the six common amino acid residues, ILE765, PHE256 and 
PHE834, to be the ligand binding site. The XP docking for these 40 ligands was repeated again 
to evaluate and confirm the previous G scores. This has given 26 out of the 40 ligands from the 
repeated XP docking with G scores of at least -10 or below. 
 
 
3.1.1.2 SPCA1d 
At the time of writing, there were no published studies investigating into the specific SPCA1 
isoforms present in basal-like breast cancer cells. Therefore, SPCA1d protein sequence was 
adopted due to its commonly expressed nature. After the SPCA1d-1SU4 homology model was 
prepared for docking, the ligand binding site was set via forming grid on LEU765, LEU256 and 
ILE834. The same process of using the three docking modes was followed for this homology 
model as the SPCA2 model. For Tim Tec set 1 ligands, HTVS docking has identified top 500 
ligands with G scores of about -6.4 and below. These 500 ligands were selected to be docked in 
SP mode by using 6 subjobs. This has generated 300 ligands with G scores of about -6.4 and 
below and subsequently put through for XP docking. However this has not produced any ligands 
with G scores of at least -10 or below. Similar XP docking results were also found for Tim Tec 
ligand set 2, 3, 4 and 5. 
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In fact, the XP docking for Tim Tec set 1 ligands have only produced 12 ligands with G scores 
between -8.0 to -9.1. For set 2 ligands, only 7 ligands had G scores between -8.1 to -8.7. For set 
3, there were 9 ligands with G scores of about -8.1 to -9.0. Only one ligand with G score of -8.2 
was present for set 4 and lastly for set 5, none of the ligands from XP docking had G scores 
above -8. Overall, the average highest G scores of -8 to -9 were found for all five set of Tim Tec 
ligands only.  
 
Because of the above result, the receptor grid was re-set again to ILE769, PHE262 and PHE854 
and named site 2, which was close to the grid for SPCA2-1IW0 model. All three docking modes 
were trialled at site 2 for all five sets of Tim Tec ligands, final results did not identify any ligands 
with XP G scores of -10 or below. Another receptor grid, site 3, was trialled again to see if this 
would make any difference. This grid was set to be on VAL761, VAL274 and ILE828 due to 
being closest to VAL769, VAL263 and ILE829 found from the SPCA2-1IW0 Venn diagram. 
Site 3 dockings had the same outcome as for site 2 docking; nil ligands had any XP G score of at 
least -10 or below. Site 4 was then generated on LEU260, LEU765 and ILE769 to trial all five 
set of ligands for docking. Similar outcome was reached except one ligand from set 3 had a XP 
G score of -10.2. Lastly, one more other grid was set up on LEU260, LEU765 and ILE837 to 
trial one more run of the three docking modes and the result for set 1 ligands was that none of the 
ligands had XP G scores of -10 or below. 
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The solution to the problem of not obtaining the expected desirable XP G scores, such as -10 or 
below, was to run SiteMap to identify any druggable sites on SPCA1d-1SU4 model. First site 
generated from SiteMap for SPCA1d-1SU4 based on residue ALA142, LEU141 and PHE236 
(SiteMap site 4) was subjected to XP docking with the previous 26 Tim Tec ligands derived from 
the SPCA2-1IW0 model. The G score range obtained from this docking ranged from -3.367 to -
6.750. The second site from SiteMap for the same homology model was set on residues LEU319, 
GLY322 and LYS251 (SiteMap site 1). This only brought G scores from -4.161 to -7.688 for the 
same set of 26 ligands. Lastly, SiteMap site 3 was selected based on ASN756, GLY808 and 
SER252 and XP docking trialled on these same set of ligands. The G score ranged from -4.235 to 
-7.973. 
 
SPCA2-1IW0 model was also trialled with these three SiteMap-derived grids for SPCA1d-1SU4 
model. SiteMap site 4 was based on ALA142, LYS141 and ARG236 (only difference was LYS 
and ARG being the different amino acid residues with exactly same residue positions as that for 
SPCA1d-1SU4 model). For SiteMap site 1, the grid was set on LEU319, GLY322 and GLN251 
(exactly same residue positions but differs in amino acid residue GLN). SiteMap site 3 had 
ASN756, GLY808 and LYS252 (same residue positions with only residue LYS different). The 
same set of 26 ligands was trialled for XP docking on these three grids with G scores ranged 
from 3.459 to -3.959 for SiteMap site 4;  -2.920 to -8.028 for SiteMap site 1; -0.641 to -11.180 
for SiteMap site 3. 
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3.1.2 SERCA 
3.1.2.1 SERCA1 
Similar receptor grids were set to all the SERCA homology models via using SiteMap.
109
 
SiteMap site 4 was set on ALA142, LYS141 and ARG236. The G scores obtained after XP 
docking of the same set of 26 ligands ranged from 0.718 to -4.108. The same XP docking of the 
26 ligands were then applied to the following three receptor binding sites. SiteMap site 1 was on 
LEU319, GLY322 and GLN251. The G scores ranged from -2.993 to -8.877. SiteMap site 3 was 
based on ASN756, GLY808 and LYS252 with G scores ranged from -3.584 to -11.423. Lastly, 
for the original TG-equivalent binding site on ILE765, PHE256 and PHE834, the G scores 
ranged from -8.812 to -11.745.  
 
3.1.2.2 SERCA2 
For SERCA2 homology model, the same four receptor grids were set up for XP docking of the 
same 26 ligands as before. For SiteMap site 4 on ALA142, LYS141 and ARG236, the G scores 
ranged from 3.624 to -5.082. For SiteMap site 1 on LEU319, GLY322 and GLN251, the G 
scores were found to range from -2.661 to -6.676. From SiteMap site 3 on ASN756, GLY808 
and LYS252, the G scores ranged from -2.976 to -11.900. For the TG-equivalent binding site on 
ILE765, PHE256 and PHE834, the G scores were found to be between -8.225 to -11.659. 
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3.1.2.3 SERCA3 
Same four receptor grids as for SERCA1 and SERCA2 models were also set up for SERCA3 
homology model. SiteMap site 4 was based on ALA142, ARG141 and ARG236. The G scores 
obtained after the XP docking of the same set of 26 ligands ranged from 2.043 to -3.865. For 
SiteMap site 1 on LEU319, GLY322 and ARG251, the G scores were found to be between -
1.169 to -8.279. The grid for SiteMap site 3 was set on ASN756, GLY808 and LYS252 and the 
G scores ranged from -1.560 to -9.397. For the TG-equivalent site on ILE765, PHE256 and 
PHE834, the G scores were between -5.597 to -11.565. 
 
3.1.3 CombiGlide results 
The details of applying CombiGlide to the six compounds selected preliminarily were elaborated 
in details on page 48 in Chapter two, the Methods section.
148
 The side-chain substitutions were 
applied to all six selected compounds and the compounds with substituted side groups were 
subjected to XP docking on SPCA1d, SPCA2, SERCA1 and SERCA3 homology models. The 
overall average G scores achieved from the CombiGlide process did not exceed the average G 
scores from the previous dockings. 
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Figure 15 
 
 
 
 
 
 
 
Figure 16 
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Figure 17 
 
The two selected ligands for SPCA1d model were compounds 3 (ZINC08846492) and 4 
(ZINC08846618) (Figure 15). From the first combinatorial library with imported Schrödinger 
fragment 1 to 50a, ZINC08846492 with fragment number 50 had the highest G score of -7.233. 
From the second combinatorial library of imported fragment 51 to 200a, ZINC08846492 with 
fragment number 154a had the highest G score of -7.049. On the same ligand with fragment 291 
from the third combinatorial library with fragment 201 to 441, the highest G score obtained was -
8.765. Several other different side-chain attachment points were also trialled and the G scores 
obtained ranged from -4.001 to -7.688. A trial was also done to attach bisphenol group onto 
ZINC08846492 and the G scores ranged from -7.027 to -7.711 (Figure 16). CombiGlide process 
was also applied to ZINC08846618. The bisphenol group was also trialled on ZINC08846618 
but only a G score of -6.377 was obtained (Figure 17). The first combinatorial library included 
Schrödinger fragments 1 to 120, the highest G score was -8.162. For the second combinatorial 
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library containing fragments 121 to 250, the highest G score was -8.972. For the third 
combinatorial library with fragments 251 to 441, the highest G score was -8.103.  
 
Figure 18 
 
For the SPCA2 model, the selected Tim Tec ligands were compounds 6 (ZINC09089406) and 
compound 5 (ZINC66088673) (Figure 18). The first combinatorial library set up contained 
fragments 1 to 170. The highest G score for ZINC09089406 was -9.347 with fragment 169. For 
ZINC66088673, the highest G score was -10.399 with fragment 39. The second combinatorial 
library had fragments 171 to 310c. The highest G score for ZINC09089406 was -8.769 for 
fragment 306b and that for ZINC66088673 was -9.276 for fragment 279. For the third 
combinatorial library, it contained fragments 311 to 441. The highest G score for ZINC09089406 
was -8.613 for fragment 394a and that for ZINC66088673 was -9.70 for fragment 429. 
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Figure 19 
 
For the SERCA1 model, the ligands selected were compound 8 (ZINC04189857) (Figure 19). 
The first combinatorial library set up had fragments 1 to 170 and the highest G score was -10.889 
for fragment 57. The second combinatorial library contained fragments 171 to 310c. The highest 
G score from the XP docking was -10.472. The third combinatorial library had fragments 311 to 
441, the highest G score was -8.64. For SERCA3 model, the selected ligand was compound 7 
(ZINC32216656) (Figure 19). The first combinatorial library had fragments 1 to 180a with the 
highest G score of -9.867. The second combinatorial library was set up with fragments 181 to 
310c and the highest G score from the docking was -9.307. The third combinatorial library 
comprised of fragments 311 to 441. The highest G score from docking was -9.869. 
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3.1.4 Results from second cycle of molecular modelling 
 
 
 
 
Figure 20 
From SciFinder, one compound was found to bear the same structure as compound 9 (from 
section 2.4.1).
151
 A trial XP docking of this compound was done on SPCA1d model with only 
the highest G score of -4.03 obtained. From PubChem, one compound with a pyrrolidone-like 
core was discovered (Figure 20).
162
 The highest G score obtained from docking this compound 
onto the SPCA1d model was -5.106. Both compounds were prepared via LigPrep prior to 
docking 
138
. 
 
BREED method was originally developed by Vertex Pharmaceuticals as an automated method to 
generate novel inhibitors from known structures of the ligands binding to target proteins.
163
 
Schrödinger has licensed and inherited this algorithm from Vertex Pharmaceuticals. The BREED 
method was accessed from the script centre under the fragment application of the Maestro 
interface. This method was applied to the structures found from the ZINC database where 22 
pyrrolidone-like and also another 26 less pyrrolidone-like structures were discovered. The 22 
pyrrolidone-like structures were subjected to the BREED algorithm and generated a total of 154 
hybrid structures. The highest G score produced from XP docking onto the SPCA1d model was -
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5.903 from these 154 hybrid structures. Also, there were altogether 182 hybrid compounds 
generated from the BREED algorithm for the 26 less pyrrolidone-like structures. The highest G 
score produced was -7.166 for the second batch of the hybrid compounds. 
 
A trial of docking CPA on SERCA1 was done to see the actual G scores produced. A total of 
three binding sites were trialled; Sitemap-generated site 1, 3 and 4. The G score obtained from 
site 3 was the highest with -6.786 which was followed by G score of -4.949 from site 1 and lastly 
a G score of -2.614 from site 4. BREED method was again used to produce hybrid molecules 
from CPA and the 26 less pyrrolidone-like structures. A total of 202 hybrid molecules were 
formed and docked on SERCA1 model. The highest G score was found to be -7.650 on Sitemap-
generated site 3. Comparing this G score with the docking of the 26 less pyrrolidone-like 
structures onto SERCA1, the highest G score of -6.081 was obtained on Sitemap site 3 and this 
score did not have a huge difference to the score for the hybrid molecule. 
 
 
 
 
 
 
Figure 21 
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The next compound trialled was artemisinin (Figure 21) as it was found to inhibit the SERCA 
orthologue of Plasmodium falciparum in Xenopus oocytes.
164
 The structure of artemisinin was 
downloaded via ZINC database and prepared via LigPrep.
138
 XP docking of artemisinin was 
done on SERCA1 model on the same Sitemap site 1, 3 and 4. The highest G score was on 
Sitemap site 1 with -3.248 only. Due to this low G score and after some considerations, a new 
receptor model of the SERCA orthologue, PfATP6, of Plasmodium falciparum was built to trial 
docking the artemisinin structure. This was done via importing the PDB structure of 1U5N into 
Maestro and using Protein Preparation Wizard to prepare the protein model. Sitemap was used 
specifically to identify any druggable sites.
109
 Two receptor grids were set up with Sitemap site 4 
based on ARG1153, LEU326 and ALA1136 and Sitemap site 1 on LEU125, VAL112 and 
ASP1038. Artemisinin was docked in XP mode on both sites with highest G score only at -2.139. 
 
Curcumin in its keto-enol form was also trialled on the SERCA1 model. The structure was 
obtained from ZINC database and was prepared via LigPrep prior to docking.
138
 The highest G 
score was found to be from Sitemap site 1 which had -5.626. Hybrid molecules were again 
produced by combining artemisinin and the 26 less pyrrolidone-like structures by using BREED 
algorithm. Altogether 189 hybrid compounds were generated. These molecules were docked 
onto the SERCA1 model in XP mode. Highest G score was -7.431 (ZINC32105134 + 
ZINC49646993; Figure 22) from Sitemap site 3. BREED method was applied to generate hybrid 
molecules by combining CPA, artemisinin, curcumin and the 26 less pyrrolidone-like structures. 
The highest G score was -7.650 which was the same hybrid molecule (ZINC04300723 + 
ZINC49647007; Figure 23) generated from the previous batch of hybrid compounds via 
merging CPA and the 26 less pyrrolidone-like structures. 
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Figure 22 
 
 
 
 
 
 
Figure 23 
A cyclic pyrazole derivative of curcumin was drawn in 2D sketcher on the Maestro interface and 
converted to 3D structure. Same process was carried out for diallyl bisphenol A, which was 
tested to inhibit SERCA.
153
 The cyclic pyrazole curcumin derivative was docked onto SERCA1 
model on Sitemap site 1, 3 and 4. The highest G score was -5.968 on site 1. Same docking was 
also applied to diallyl bisphenol A on SERCA1 with the same three binding sites. The highest G 
score found was -6.348. LEU61, VAL62, LEU65, ILE97, LEU253, ILE307, PRO308, LEU311 
and PRO312 were found to be the hydrophobic residues interacting with most of the non-polar 
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parts of the bisphenol inhibitors as suggested by Woeste et. al.
153
 ASP254 was also found to be 
the critical amino acid residue interacting with the hydroxyl group of bisphenol inhibitors via 
hydrogen bonding. Therefore, a new grid was formed on SERCA1 on ASP254, ILE97 and 
PRO312. The two prepared diallyl bisphenol A were docked onto this new binding site with the 
highest G score of -4.803. The original CPA binding site on SERCA was also trialled with the 
grid set on GLN56, LEU61 and ASN101.
40
 The G score obtained was -4.418. 
 
3.1.5.1 Results from first cycle of compound selection 
The G scores and MM-GBSA results facilitated the final compound selection for biological 
testing. From the 26 ligands identified from the docking process on the SPCA2 model, six 
compounds were preliminarily selected. These six compounds were chosen on the basis of 
possessing G scores of at least -7 or below with reasonable MM-GBSA results of binding energy 
between the ligand and receptor (Table 4). Even though CombiGlide was trialled on the six 
preliminarily selected compounds, the overall average G scores did not surpass the previous G 
scores obtained. Therefore two compounds, ZINC08846492 (compound 3) for SPCA1d and 
ZINC04189857 (compound 8) for SERCA1, were selected to be purchased from Tim Tec out of 
the six compounds selected originally. 
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Screening compounds for 1SU4-SPCA1d 
 
Properties Scores 
ZINC08846492
 
XP G Score -7.688 
MMGBSA dG bind 
energy 
-90.593513 
Ligand strain 
energy 
13.58 
Prime energy  
(of the complex) 
45305.1 
ZINC08846618 
 
XP G Score -7.027 
MMGBSA dG 
Bind energy 
-85.14 
Ligand strain 
energy 
38.47 
Prime energy  
(of the complex) 
45276.3 
Table 4  Six pre-selected compounds with corresponding G scores and MM-GBSA results 
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Screening compounds for  
1IW0-SPCA2 
Properties Scores 
ZINC09089406 
 
XP G Score -8.028 
MMGBSA dG Bind 
energy 
-71.092079 
Ligand strain energy 8.62 
Prime energy 
(of the complex) 
-40069.1 
ZINC66088673 
 
XP G Score -11.116 
MMGBSA dG Bind 
energy 
-70.420023 
Ligand strain energy 6.68 
Prime energy 
(of the complex) 
-40065.8 
Table 4 (continued) Six pre-selected compounds with corresponding G scores and MM-GBSA results 
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Table 4 (continued) Six pre-selected compounds with corresponding G scores and MM-GBSA result 
 
 
 
 
 
Screening compounds for 3AR5-SERCA1 
 
Properties Scores 
ZINC04189857
 
XP G Score -10.917 
MMGBSA dG 
Bind energy 
-78.466592 
Ligand strain 
energy 
4.425 
Prime energy  
(of the complex) 
-26763.2 
Screening compounds for 3AR4-SERCA2 
(same compound as 3AR5-SERCA1) 
Properties Scores 
ZINC04189857
 
XP G Score -11.9 
MMGBSA dG 
Bind energy 
-77.767271 
Ligand strain 
energy 
7.721 
Prime energy  
(of the complex) 
-41203.8 
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Screening compounds for 3AR7-SERCA3 
 
Properties Scores 
ZINC32216656 
 
XP G Score -9.17 
MMGBSA dG 
Bind energy 
-85.252258 
Ligand strain 
energy 
1.982 
Prime energy  
(of the complex) 
-41040.2 
Table 4 (continued) Six pre-selected compounds with corresponding G scores and MM-GBSA results 
 
 
3.1.5.2 Results from second cycle of compound selection 
The initial draft selection of compounds that had the most potential to be the testing compounds 
were two of the hybrid molecules generated from the BREED method. These hybrid molecules 
had the top two G scores which were ZINC04300723 + ZINC49647007 (Figure 23) with a G 
score of -7.650 and ZINC32105134 + ZINC49646993 (Figure 22) with a G score of -7.431. 
Other potential compounds considered were the diallyl bisphenol A, curcumin and cyclic 
pyrazole derivative of curcumin. All of these three compounds had G scores higher than that for 
CPA relatively. Therefore, it was decided to synthesise these compounds in the laboratory 
(compounds 12, 13, 15, 16 and 17). The two hybrid molecules however had complex 
stereochemistry and were not readily available commercially hence they were not chosen to be 
synthesised at this stage. Also in collaboration with the honours students, another compound 
with a similar structural core was also decided to be tested (compound 10). 
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3.2 Dose - response curves from FLIPR 
FLIPR testing was based on the principle of SOCE which was explained in details in Chapter 
one. The results were presented in the Ca
2+
 response or dose-response (for compounds 3 and 8 
only) curves with two distinctive Ca
2+
 peaks shown. This was one of the standard experimental 
protocols used to examine and study the Ca
2+
 influx phase in details.
16
 A small Ca
2+
 increase 
occurred initially when the remaining Ca
2+
 in ER leaked out from IP3R while ER was blocked by 
CPA or tested compounds.  This was then followed by a slow reduction in Ca
2+
 response as the 
intracellular Ca
2+
 returned to its basal level. Overall this was represented by the first Ca
2+
 peak. 
After the addition of Ca
2+
, there would be a larger Ca
2+
 influx, represented by the second Ca
2+
 
peak. An example of graphical interpretation of these two Ca
2+ 
peaks could be seen in Figure 24. 
 
 
 
 
 
 
 
 
 
Figure 24  Example of a Ca
2+
 response profile (taken from ref. 16)  
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From the first two compounds tested (compound 8 – ZINC04189857 and compound 3 – 
ZINC08846492), dose–response curves were generated based on the first and second Ca2+ peaks 
produced after treating the MDA-MB-231 cells. These peaks were compared with the Ca
2+
 peaks 
from the control, CPA. Compound 8 was not adequate to generate any dose response for the first 
Ca
2+
 peak. The second peak from compound 8 only managed to produce a very minimal Ca
2+ 
response when compared to that from CPA. On the other hand, compound 3 was able to generate 
a slightly better dose response on the first Ca
2+
 peak than that from compound 8. The second 
Ca
2+
 peak after compound 3 treatment only produced a similar minimal dose response as from 
compound 8 treatment. Both compounds did not elicit significant Ca
2+
 dose response in the 
MDA-MB-231 cells as CPA. The comparison results could be seen in Figure 25 with the 
individual dose-response curves shown in Figure 26. 
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Figure 25 Comparison dose response curves for compound 8 or C1 (ZINC04189857), compound 3 or 
C2 (ZINC08846492) and CPA. Peak 1 represented the first Ca
2+
 peak and peak 2 represented the second 
Ca
2+
 peak from the FLIPR testing (M = Molar concentration in semi-logarithmic plot) 
Calcium peak 1 CPA vs C1
0.8
1.0
1.2
1.4
1.6
-8 -7 -6 -5 -4
CPA
Compound 1
(ST4045533)
Agonist concentration (M)
M
a
x
 r
e
s
p
o
n
s
e
Calcium peak 2 CPA vs C1
0
2
4
6
8
-8 -7 -6 -5 -4
CPA
Compound 1
(ST4045533)
Agonist concentration (M)
M
a
x
 r
e
s
p
o
n
s
e
Calcium peak 1 CPA vs C2
0.8
1.0
1.2
1.4
1.6
-8 -7 -6 -5 -4
CPA
Compound 2
(ST4081102)
Agonist concentration (M)
M
a
x
 r
e
s
p
o
n
s
e
Calcium peak 2 CPA vs C2
0
2
4
6
8
-8 -7 -6 -5 -4
CPA
Compound 2
(ST4081102)
Agonist concentration (M)
M
a
x
 r
e
s
p
o
n
s
e
Peak 1 C1 vs C2
0.90
0.95
1.00
1.05
1.10
1.15
1.20
-8 -7 -6 -5 -4
Compound 1
(ST4045533)
Compound 2
(ST4081102)
Agonist concentration (M)
M
a
x
 r
e
s
p
o
n
s
e
Peak 2 C1 vs C2
1.2
1.3
1.4
1.5
1.6
1.7
1.8
-8 -7 -6 -5 -4
Compound 1
(ST4045533)
Compound 2
(ST4081102)
Agonist concentration (M)
M
a
x
 r
e
s
p
o
n
s
e
89 
 
 
Figure 26  Individual dose response curves for compound 8 (Compound 1 or ZINC04189857), compound 3 
(Compound 2 or ZINC08846492) and CPA. Peak 1 represented the first Ca
2+
 peak and peak 2 represented the 
second Ca
2+
 peak from the FLIPR testing (M = Molar concentration in semi-logarithmic plot) 
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3.3 Intracellular calcium response curves from FLIPR 
3.3.1 Results for compound 8 (ZINC04189857) and compound 3 (ZINC08846492) 
The Ca
2+ 
response curves were obtained from the FLIPR and shown in the following figures. 
These figures demonstrated the details of the intracellular Ca
2+ 
signalling over time within the 
MDA-MB-231 cells after these two compound treatments when compared to the control groups, 
CPA and DMSO. Figure 27 was composed of the different compound concentrations applied to 
the MDA-MB-231 cell line. It demonstrated the first Ca
2+
 peak when BAPTA and compound 8 
and 3 were added. The most prominent Ca
2+
 peaks that could be easily observed at the top were 
from CPA treatment with concentrations from 10 µM, 3 µM and 1 µM. The lower ranges of 
CPA concentrations were buried within the compound 8 and 3 groups. All of the compound 8 
and 3 concentrations used only provided a Ca
2+
 response from 0.75 to 1.0 over the baseline Ca
2+
 
response. In another words, there were no Ca
2+
 peak generated when compound 8 and 3 were 
applied to the cell line. 
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Figure 27  Agonist concentrations of CPA, Compound 8 (C1 or ZINC04189857) and Compound 
3 (C2 or ZINC08846492) versus Ca
2+
 response over time (zoom-in for first Ca
2+
 peak) 
 
For Figure 28, this showed the second Ca
2+
 peak when Ca
2+
 was added to the MDA-MB-231 
cell line. Again the most obvious peaks were from the CPA treatment (positive control group). 
The easily seen CPA concentrations were also the same as that for the first Ca
2+
 peak, for 10 µM, 
3 µM and 1 µM but also included the 0.3 µM. Compound 8 in 3 µM was the highest 
concentration to give a slightly higher second Ca
2+
 peak than the rest of the concentrations for 
both Compound 8 and 3. Overall the second Ca
2+
 signals were very weak for both compound 8 
and 3 when compared with our control, CPA group. Figure 29 demonstrated the overall Ca
2+
 
response for all concentrations of all three tested agonists, compounds 8, 3 and CPA. 
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Figure 28  Agonist concentrations of CPA, Compound 8 (C1 or ZINC04189857) and Compound 
3  (C2 or ZINC08846492) versus Ca
2+
 response over time (zoom in for second Ca
2+ 
peak) 
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Figure 29  Agonist concentrations of CPA, Compound 8 (C1 or ZINC04189857)  and Compound 
3  (C2 or ZINC08846492) versus Ca
2+
 response over time  
 
Figure 30 only included the top four concentrations for all three agonist treatment groups for the 
ease to observe the Ca
2+
 response clearly. The concentrations ranged from 0.1µM to 10µM for 
all three agonist groups. A similar Ca
2+
 signalling effect was seen as from the previous figures. 
Both compound 8 and 3 did not generate significant first and second Ca
2+
 peaks. This was 
especially clear in the enlarged zoom-in graphs for first and second peaks. The peaks generated 
from CPA again were the standard SERCA inhibitor Ca
2+
 signalling curves in the cell line as 
seen in the figure. 
94 
 
 
10uM CPA
10uM C1
3uM CPA
3uM C1
3uM C2
1uM CPA
1uM C1
1uM C2
0.3uM CPA
0.3uM C1
0.3uM C2
0.1uM C2
Read_Mode_1
Average Graph
Time (Seconds)
100 200 300 400 500 600 700
R
e
s
p
o
n
s
e
 o
v
e
r 
B
a
s
e
lin
e
0.8
1
1.2
1.4
 
Figure 30  Top four agonist concentrations for three treatment groups (Top: zoom-in for first 
Ca
2+
 peak  Bottom: zoom-in for second Ca
2+
 peak)(C1 = compound 8  C2 = compound 3) 
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Figure 30 (continued)  Top four agonist concentrations for three treatment groups (Top: zoom-in 
for first Ca
2+
 peak  Bottom: zoom-in for second Ca
2+
 peak)(C1 = compound 8  C2 = compound 3) 
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Figure 31 has focussed on just the top three agonist concentrations for all three treatment groups. 
First Ca
2+
 peaks for both compounds 8 and 3 at all concentrations only produced flat Ca
2+
 
response when compared with our positive control group, CPA. However for the second Ca
2+
 
peak, both compounds 8 and 3 produced a small increase in Ca
2+
 response after Ca
2+
 was added. 
Overall the small Ca
2+
 increase for second peak was not large enough to warrant a resemblance 
to the positive control. Figure 32 again showed only the top two agonist concentrations for all 
three treatment groups with similar outcome as mentioned previously. 
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Figure 31  Top three agonist concentrations for three treatment groups (Top: zoom-in for first 
Ca
2+
 peak  Bottom: zoom-in for second Ca
2+
 peak) (C1 = compound 8  C2 = compound 3) 
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Figure 31 (continue)  Top three agonist concentrations for three treatment groups (Top: zoom-in 
for first Ca
2+
 peak  Bottom: zoom-in for second Ca
2+
 peak) (C1 = compound 8  C2 = compound 
3) 
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Figure 32  Top two agonist concentrations for three treatment groups (C1 = compound 8  C2 = 
compound 3) 
 
For Figures 33 and 34, the positive control group, CPA, was compared individually with both 
compounds 8 and 3. Only the top two concentrations were shown in the figures. Both 
compounds 8 and 3 were very similar in their overall Ca
2+
 signalling profiles. In Figure 35, the 
three agonist treatment groups were compared with the negative control, DMSO. Clearly the top 
two concentrations of CPA demonstrated the typical SERCA inhibitor Ca
2+
 response curves. 
Both compounds 8 and 3, on the other hand, were much less prominent but when compared with 
our negative control group, the Ca
2+
 responses were still slightly higher than that for DMSO 
(shown as 0 µM of CPA, compounds 8 and 3). The DMSO concentration used in the experiment 
was set at 4µL/mL. The direct comparisons between 10 µM of compound 8 and 3 µM of 
compound 3 against DMSO were shown in the figures. Here the slight increments in Ca
2+ 
were 
present but smaller when compared with the figure consisting 10 µM of CPA against DMSO. 
Figures 36, 37 and 38 have shown the top four concentrations of CPA, compounds 8 and 3 
against DMSO to reveal the differences between each agonist.  
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Figure 33  Top two concentrations of CPA versus Compound 8 (C1 or ZINC04189857) 
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Figure 34  Top two concentrations of CPA versus Compound 3 (C2 or ZINC08846492) 
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Figure 35  Top two concentrations of three agonist treatments versus DMSO (4µL/mL)  
(C1 = compound 8  C2 = compound 3) 
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Figure 36  Top four concentrations of CPA versus DMSO (4µL/mL)  
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Figure 37  Top four concentrations of Compound 8 (C1 or ZINC04189857) versus DMSO (4µL/mL) 
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Figure 38  Top four concentrations of Compound 3 (C2 or ZINC08846492) versus DMSO (4µL/mL) 
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3.3.2 Results for compounds 10, 13, 15, 16 and 17 
 
 
 
Figure 39  Ca
2+
 response for compound 17 (JL-2CV) 
 
Figure 39 provided the Ca
2+
 response for compound 17. At the beginning, there seemed to be an 
increase of the Ca
2+
 signalling but in fact this increase was due to compound addition artefact 
from the FLIPR. The dark green line represented the negative control, DMSO. The rest of the 
three lines represented three concentrations of compound 17 in 1 µM, 10 µM and 100 µM used 
in the FLIPR testing. Overall, there were no significant changes or increase in Ca
2+
 signalling of 
compound 17 when compared with DMSO. 
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Figure 40  Ca
2+
 response for compound 13 (JL-2) 
 
The Figure 40 showed the Ca
2+
 signalling profile of compound 13 compared with DMSO at 
100µM. Three different concentrations of compound 13 were used, starting with the lowest 
concentration of 1 µM and then increasing to 10 µM and 100 µM. DMSO was represented by the 
dark green line. Both 1 µM and 10 µM of compound 13 did not generate any increased Ca
2+
 
signalling when compared with DMSO. At 100 µM of compound 13, a significantly higher Ca
2+
 
was observed by a first Ca
2+
 peak and also a second Ca
2+
 peak which was not recovered but 
sustained throughout the process. The sustained second Ca
2+
 peak was different from the Ca
2+
 
signalling profile from CPA, where the second Ca
2+
 peak would recover back to baseline 
response. On the other hand, a contrast in the Ca
2+
 response was seen in compound 15 at 100 µM 
from compound 13 in Figure 41. All three concentrations of compound 15 did not produce 
prominent Ca
2+
 response as that from CPA at 10 µM. These concentrations were in fact more in 
line with the effect from DMSO. 
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Figure 41  Ca
2+
 response for compound 15 (JL-5) 
 
 
 
 
 
 
Figure 42  Ca
2+
 response for compound 10 (QG-05) 
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Figure 43  Ca
2+
 response for compound 16 (JL-1C) 
 
In Figure 42, DMSO was shown in dark green line and compared with three other 
concentrations of compound 10. The Ca
2+
 signalling profiles for both 1 µM and 10 µM of 
compound 10 were very similar to the Ca
2+
 response from DMSO. Only the 100 µM of 
compound 10 produced a higher Ca
2+
 response. There was a higher first Ca
2+
 peak and the 
second peak had a slight recovery towards the end of 1800 seconds. For Figure 43, compound 
16 was tested in three concentrations, 1 µM, 10 µM and 100 µM. Compound 16 in 1 µM had not 
much difference to DMSO but with 10 µM of compound 16, a higher first and second Ca
2+
 peaks 
were shown. At 100 µM of compound 16, an even higher Ca
2+
 response was shown than at 10 
µM. 
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Figure 44  Ca
2+
 response for all five tested compounds at 10 µM 
 
 
Figure 45  Ca
2+
 response for all five tested compounds at 100 µM 
106 
 
In Figure 44 comparing all five compounds with CPA and DMSO at 10 µM, it was clearly 
shown that compound 16 had a higher Ca
2+
 response than the rest of the tested compounds 
including DMSO. CPA itself gave the standard Ca
2+
 signalling profile with the highest response 
out of all compounds tested. The comparison of all five compounds with CPA and DMSO at 100 
µM was given in Figure 45. There were four out of five tested compounds that had higher Ca
2+
 
responses than compounds 17, 10 and DMSO. Compound 13 had higher Ca
2+
 response than CPA 
whereas the first Ca
2+
 peak response for compound 16 was higher than CPA but its second Ca
2+
 
peak did not exceed that from CPA. 
 
 
3.4 DISCUSSION 
3.4.1 Evaluation of molecular modelling results 
3.4.1.1 SPCA 
The molecular modelling process began with ascertaining the ligand binding site of a well-
known SERCA inhibitor, TG, on the first Ca
2+
 ATPase model, SPCA2. Therefore the TG 
binding site was used on this model for the initial virtual screening of the TimTec compounds 
derived from the ZINC database.  
 
The molecular docking began from screening all downloaded Tim Tec compounds on the 
SPCA2 model. The number of subjobs was reduced from 16 to 6 in the HTVS docking because 
there were only limited numbers of Glide licence available for the project. If the number of 
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subjobs exceeded the number of Glide licence present, the running of the subjobs would be 
terminated which meant no results would be available after the Glide docking. Consequently this 
might reduce the number of ligands with desirable G scores for further investigation. The 
number of subjobs used in the entire docking process was kept at 6 unless otherwise stated to 
avoid variations in the docking results between different Ca
2+
 ATPase models.  
 
A Venn diagram was compiled after completing all three stages of docking modes, from HTVS 
to SP and finally the XP docking mode. The purpose of the Venn diagram was to differentiate 
the ligand-interacting amino acid residues on the SPCA2 model. It was essential to identify the 
exact ligand binding site by knowing which amino acid residues were involved. Altogether there 
were six amino acid residues found after analysing the ligand-interacting residues from 40 Tim 
Tec ligands. This would assist in finding the desirable ligand binding sites for further compound 
docking on the SPCA1d model and subsequently on all three SERCA homology models. Three 
of the six amino acid residues (ILE765, PHE256 and PHE834) were randomly chosen and set as 
the ligand binding site and XP mode docking trialled for the second time on the 40 Tim Tec 
ligands. This was to confirm this binding site would give at least similar G scores of -10 or 
below. At the end, 26 out of the 40 compounds gave this G score. 
 
For the SPCA1d model, the first ligand binding grid was set on LEU765, LEU256 and ILE834. 
The only difference here was that the amino acid residues were different from the one used for 
the second trial for the SPCA2 model, which had isoleucine (ILE) and two phenylalanines (PHE) 
on position 765, 256 and 834 respectively. Four other different ligand binding grids were also set 
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up as described in details in the Results Section. A combination of three amino acid residues 
with either same amino acid residues or same residue position number as the previously found 
six residues from the Venn diagram was used. None of the docking results reached the G score of 
at least -10 as before. This could be attributed to the difference in the ligand binding site set with 
variable amino acid residues and positions present. The molecular binding and interaction would 
change drastically from the previous ligand-receptor bindings on the SPCA2 model. 
Subsequently this could affect the G scores obtained in the selected Tim Tec ligands. This 
outcome was reflected in the docking from the SPCA1d model. 
 
In an attempt to resolve the issues with the lower G scores obtained from SPCA1d docking, 
SiteMap was employed to identify new druggable sites on the SPCA1d model. Three new 
binding sites were found and the 26 Tim Tec ligands previously found to have relatively high G 
scores were trialled for docking on these three sites. The G scores reached for all three binding 
sites did not actually reach -10 with the highest of only about -7.9 for SiteMap-derived site 3. 
Oppositely, another trial was also carried out on SPCA2 model to test these three SiteMap-
derived sites. The specific grids were described in details in the Results section. The highest G 
score obtained here was about -11 from SiteMap site 3. The rest of the ligands had lower G 
scores than -11 which were also the same for the result from the docking on SPCA1d model. The 
possibilities of not acquiring the expected high G scores could be due to two main reasons. 
Firstly, only the 26 found Tim Tec ligands were used for ligand docking on the three SiteMap-
derived sites for both SPCA2 and SPCA1d models. The outcome could have been different if the 
original whole five sets of Tim Tec ligands were subjected to HTVS, SP and XP mode dockings. 
Secondly, the accuracy of the homology models might not have reflected the real-life protein 
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models of SPCA2 and SPCA1d. At the time of constructing these homology models, there were 
no actual crystal structures of SPCA2 and SPCA1d available from human source. This was 
therefore taken into account to the best possible extent by building these SPCA2 and SPCA1d 
models based on human-sourced protein sequences. 
 
3.4.1.2 SERCA 
Homology models for all three isoforms of SERCA were constructed based on human-sourced 
SERCA protein sequences. The same three SiteMap-derived sites were used for SERCA1, 2 and 
3 models. Again a combination of amino acid residues at the same positions were used for 
setting up the ligand binding grids but the amino acid residues might not be exactly the same as 
the initial ones found from SPCA1d model. The highest G score found from XP docking of 
SERCA1 model was about -11.7 from the original TG-based site derived from SPCA2 docking. 
 
The same four binding sites were also applied to SERCA2 model, which included the original 
TG-equivalent site. XP docking was done for all four sites with the same set of 26 Tim Tec 
ligands. The highest G score was about -11.9 from SiteMap-derived site 3. For SERCA3 model, 
the same docking process was applied on the four binding sites. The highest G score was about -
11.5 from the TG-equivalent site. Overall, all three SERCA models produced similar docking 
results. 
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3.4.1.3  Evaluation of CombiGlide results 
The main reason of adopting and trialling CombiGlide in the molecular docking process was to 
attempt maximising the number of compound hits with G scores of about -10 or below. This 
programme suite was designed to allow substitutions of side-chain groups or so-called 
“fragments” of the chemical compounds in the in silico context. This allowed more time and 
flexibility without putting in high expenditure into the chemical synthesis in order to pre-empt 
the first-hand effect of substituted compound on the desired receptor target. However, downfalls 
of this technique could be that it was nonetheless only an in silico simulation and not a real-life 
representation of the compound-receptor binding so the result from this application might not 
lead to the expected experimental outcome. 
 
CombiGlide was applied to the six compounds selected after the completion of all the docking 
processes for SPCA2, SPCA1d and all three SERCA models. There were in total 667 fragments 
downloaded from the Schrödinger website. Two compounds (ZINC08846492 and 
ZINC08846618; Figure 15) were selected from the docking process for SPCA1d model and 
subjected to fragment substitutions in CombiGlide. An average G score of -7.78 was obtained 
from the CombiGlide trial on SPCA1d model. The highest G score obtained was -8.972 from 
ZINC08846618. For SPCA2 model, there were also two Tim Tec ligands selected 
(ZINC09089406 and ZINC66088673; Figure 18) for fragment substitutions. A higher average G 
score of -9.35 was reached for the compounds chosen from SPCA2 docking than from SPCA1d 
model. The highest G score was -10.399 from ZINC66088673. 
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The compound selected after evaluation of the docking results from SERCA1 and SERCA2 
models was ZINC04189857 (Figure 19), which was subjected to fragment substitutions. The 
average G score resulted was -10.0. The highest G score found was -10.889. For SERCA3 model, 
the selected ligand was ZINC32216656 (Figure 19). The highest G score was -9.869 and an 
average G score of -9.68 were achieved. Overall, after close evaluation, none of the G scores 
obtained from CombiGlide were higher than the original G scores reached from previous 
dockings. Therefore, it was decided not to change any of the six compounds selected previously 
for experimental testing. 
 
One critical factor influencing the docking result of the substituted compounds on the targeted 
receptor model was that the fragment substitution point was randomly chosen. This meant that 
there was no systematic or consistent point of substitution of each fragment onto the selected 
ligand. This undoubtedly would affect the docking results to a certain degree, such as variability 
in G scores from XP mode docking. Potentially a change in the ligand-receptor binding affinities 
and energies due to changes in molecular interactions would also be reflected if this was 
specifically investigated. However, due to the time constraint and project aims, this was not 
particularly looked into. Therefore it would be more valuable to investigate the impact of 
substituting fragments at set points or randomly selected points on a chosen compound structure 
and evaluate the outcomes both in silico and experimentally. 
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3.4.2 Evaluation of the results from tested compounds 
3.4.2.1 Compound 8 and compound 3 
Since CombiGlide trial did not produce any superior G scores than previously obtained, it was 
decided to test two of the compounds out of the chosen six which aimed to target SPCA1d and 
SERCA1 models. The final chosen compounds were ZINC04189857 (compound 8) and 
ZINC08846492 (compound 3). Compound 8 was selected to target SERCA1 and Compound 3 
was to target SPCA1d. There were no compounds chosen to target SPCA2 since this was not the 
exact target SPCA isoform for basal-like breast cancer. Hence, one compound was chosen to 
target SPCA1d and another compound was selected to target SERCA1. 
 
At the initial testing stage and also due to time constraint of the project, both compounds 8 and 3 
were purchased from the commercial chemical supplier, Tim Tec. Approximately 20mg of both 
compound 8 and 3 were purchased and samples of about 1 mg of each compounds were 
examined by NMR spectroscopy to ensure the compounds purity. The NMR spectrums for both 
compounds 8 and 3 confirmed their purity. 
 
The first biological testing of these compounds involved using FLIPR to measure the Ca
2+
 
signalling activities within the MDA-MB-231 cells after compound treatment. Our positive 
control in this project was CPA, a well-known SERCA inhibitor in the literature.
38,40
 The 
negative control used in the experiment was DMSO which was used at a concentration of 
4µL/mL for each well of the 96-well plate. Ca
2+
 ions were added before 800 seconds in order to 
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show whether the calcium pumps in the sarcoplasmic reticulum were functioning as expected 
theoretically in the breast cancer cells when Ca2+ ions were present intracellularly. Similar 
fluorescent-based intracellular calcium level testings were also adopted in other previous 
studies.
153,165
 The result would provide first-hand comparison between the tested agents and the 
control agonist, CPA. 
 
The result outputs from FLIPR were shown as a series of Ca
2+
 response curves over time (see all 
figures in Results Section). All the data obtained from FLIPR have been normalised at baseline 
to ensure all treatment groups started at the same time point. CPA itself showed a standard two-
Ca
2+
 peak curves. The first Ca
2+
 peak came from the inhibition of the SERCA which prevented 
the Ca
2+
 to be sequestered into the sarcoplasmic reticulum. Hence these Ca
2+ 
were present within 
the cells and would be measured and presented as the peak on the Ca
2+
 response curves. 
However other Ca
2+
 channels, such as PMCAs, would still be functioning at the time when 
SERCA was inhibited by CPA. Therefore, some Ca
2+
 would be able to gain entry into the 
organelles present within the cells such as sarcoplasmic reticulum or Golgi network. In this case, 
the level of Ca
2+
 would then slowly drop. This process was represented by the first peak in the 
Ca
2+
 response curves. The second Ca
2+
 peak arrived after more Ca
2+
 ions were added into the 
cells to demonstrate a higher intracellular Ca
2+ 
level than the first peak to help differentiating the 
different Ca
2+
 effects inside the breast cancer cells.  
 
When compound 8 was added to the MDA-MB-231 cells, there was no significant first Ca
2+
 
peak effect when compared to that from CPA. Figure 27, a zoom-in shot for first calcium peak, 
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showed relatively flat Ca
2+
 responses for compound 8. This finding also applied to effect from 
compound 3 where there was no obvious Ca
2+
 peaks observed. Only the 10 µM, 3 µM and 1 µM 
CPA have demonstrated the first Ca
2+
 peak. It could also be noticed that before 350 seconds, the 
Ca
2+
 response readings were in zigzag lines for all three treatment groups and not as smooth as 
the readings after 350 seconds. This was due to the FLIPR reading the Ca
2+
 signals once every 
second before 350 seconds. After this time point, FLIPR was reading the Ca
2+
 signals once every 
ten seconds which was the default setting of the FLIPR. 
 
Figure 28 had the enlargement of the second Ca
2+
 peaks for all concentrations tested for the 
three agonists mentioned. A prominent difference could be seen between the Ca
2+
 peaks from 
CPA and compounds 8 and 3. Again the same three Ca
2+
 concentrations for CPA provided the 
significant higher Ca
2+
 peaks which gradually recovered as time passed. The fourth highest Ca
2+
 
peak seen for CPA was the 0.3 µM which could just be seen slightly above the rest of the flat 
Ca
2+ 
response curves from compounds 8 and 3. It could also be observed that there were a subtle 
increase in Ca
2+
 signals for both compounds 8 and 3 treatment groups. This effect could be 
confirmed from Figure 35 which compared the Ca
2+
 signals between the three agonist groups 
with DMSO. Only the top two concentrations for all three agonist treatment groups were 
compared with DMSO, which were represented by 0 µM CPA, 0 µM C1 and 0 µM C2 in the 
figure.  
 
Figure 30 demonstrated the top four concentrations of all three agonist treatment groups. It 
compared between CPA, compounds 8 and 3 in concentrations of 10 µM, 3 µM, 1 µM, 0.3 µM 
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and 0.1 µM. Compound 3 had poor solubility in DMSO and hence the highest concentration 
reachable was at 3 µM. Here the zoom-in graphs of the first and second Ca
2+
 peaks clearly 
showed a much weaker Ca
2+
 response for both compounds 8 and 3 as discussed above. This 
again could be confirmed in Figures 33 and 34 where both compounds 8 and 3 only produced a 
very low and weak Ca
2+
 response when compared individually with CPA. 
 
3.4.2.1.1 Limitations from molecular modelling and FLIPR testing 
One interesting aspect of the Ca
2+
 signalling effects shown in Figure 28 was that the Ca
2+
 
response for 3 µM CPA was higher than 10 µM CPA. In the expected outcome, the Ca
2+ 
response would have been higher for the higher CPA concentration group than a lower 
concentration treatment. This could be due to the inevitable variations in the processes and 
handling of cell culture and plating, reagent plate preparations and fluorescent dye treatment. 
Throughout the process of cell culture and plating, it could be possible to have plated the cells 
unevenly in some of the wells in the 96-well cell plate. Uneven cells in the well could lead to 
variations in the FLIPR fluorescent signal readings. Another probable reason could be due to 
human error which might involve mixing up the 10 µM and 3 µM CPA well additions during the 
reagent plate preparation process. It was also possible that there were remnants of the Fluo-4-
AM dye in the 3µM CPA wells even though the plate was washed at least twice throughout the 
process. In this case this could lead to a higher reading of the Ca
2+
 signals in the 3 µM CPA 
wells. 
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From the calcium response curves obtained for CPA, compounds 8 and 3, it was evident to 
suggest that both compound 8 and 3 did not perform as expected. This could be attributed to two 
major factors where the accuracy of molecular modelling and the assay method used in this 
project might have contributed to this outcome. The compound selection for biological testing 
was influenced heavily from the molecular modelling. It was noticed that choosing compounds 
based on G scores and MM-GBSA results might not be adequate as docking scores were not 
considered as one of the factors during the compound selection process. It was also observed that 
in some cases of the ligand-receptor docking, the docking scores and G scores were exactly the 
same but in some other cases they differed to a large degree. Docking scores were almost like G 
scores, except they also took into account of the Epik penalty of the binding complex. For this 
reason, to further improve the accuracy of choosing the compound with highest potential to 
target the desirable molecular target, it would be necessary to also take into account the docking 
scores for each ligand-recpetor bindings during the ligand selection process.  
 
Because of the unavailability of SPCA1d crystal structure at the beginning of the project, in 
silico homology model of SPCA1d had to be built and generated. The accuracy of the SPCA1d 
homology model to the real-life SPCA1d protein crystal structure was not possible to be 
confirmed at the time of the project. However it would be fair to point out that this SPCA1d 
homology model was likely not a true reflection of real SPCA1d protein structure since it was 
only an in silico simulation of the protein structure. This would also have an impact on 
identifying the correct target binding sites on the homology model since the identified binding 
sites for the screened ligands might not be the actual ligand binding sites on the model.
166
 As a 
result, there was a high degree of inaccuracy in the attempt to design effective SPCA1d 
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inhibitors. The only factor that might give the project results with some more credibility was that 
human-sourced SPCA1d protein sequence was used to produce the SPCA1d homology model. 
Then a SERCA orthologue was chosen as the structure base for the SPCA1d homology model. 
The accuracy of the SPCA1d receptor model would be greatly enhanced and improved if there 
were human-sourced crystal structures for SPCA1d available in the future. 
 
Another important aspect of molecular modelling limitation was the LigPrep process for the 
ligands selected for docking. All the Tim Tec ligands downloaded from the ZINC database have 
not been subjected to LigPrep prior to docking which began from HTVS to SP and lastly to XP 
mode as discussed previously. This might have potentially affected the virtual screening result 
which might have reduced the number of potential compounds for biological testing. However, 
the LigPrep step was not undertaken previously since it was also suggested by Schrödinger that 
ZINC database usually provided the prepared 3D databases which used Epik for state generation 
therefore those structures could be used directly for virtual screening such as in Glide. 
Nevertheless, it was also later understood that in order to achieve the most optimal results, it 
would be wiser to prepare all ligands with LigPrep prior to any docking process. 
 
It was also worth noting that even if LigPrep was applied to each of the downloaded ligand, there 
would still be some limitations present to the LigPrep application itself. LigPrep has not been 
subjected to extensive testing for preparing ligands other than largely organic and drug-like 
molecules 
138
. Some degrees of uncertainty would exist after the LigPrep process was applied to 
the ligands outside this molecule class. It was possible that some of the downloaded Tim Tec 
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ligands might be outside the tested molecule class and hence would lose the chance of being 
submitted into the docking process. Another limitation would be that some of the input structures 
might be lost during the LigPrep process due to difficult in silico structure preparation. 
Problematic structures would thus not be reflected in the output structure file and this would 
reduce the number of ligands for the docking process. The file size of input ligand structures 
could also limit the number of structures for the computers to process. The larger the number of 
input structures such as 150,000 ligands or above might place a considerable strain on the 
computer operating system and also the hardware. In this project, about 271,965 compounds 
were screened. However, not all of the screened compounds were subjected to LigPrep all at 
once but splitted in sets of five. 
 
Another area for improvement involved refining and checking the compound stereochemistry.  
Even though LigPrep process would take into account the stereochemical factors but as 
mentioned above, the ZINC database-derived Tim Tec compounds were not put through the 
LigPrep process. This also meant that the stereochemistry of all Tim Tec ligands was overlooked 
during the molecular modelling step. As suggested by Brooks et. al., it was recommended to 
check the stereochemistry of the ligand-like compounds prior to virtual screening process.
139
 If 
the aspect of checking compound stereochemistry was neglected, there was a potential risk of 
losing a significant proportion of potential lead compounds. This would thus deeply impact the 
outcome of the biological assays. It was also noteworthy to consider another scenario where even 
if LigPrep was used for all the downloaded ligands, it would also be useful to check the 
stereochemistry of the ligands to see if the application has corrected the compound 
stereochemistry. 
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3.4.2.2 Compounds 10, 13, 15, 16 and 17 
The second cycle of virtual screening began after the first two compounds were selected and 
tested in FLIPR. The structures of compounds 8 and 3 and CPA were reviewed and compared. A 
common structural theme to both CPA and compound 3 were deduced and found. The structural 
motif was shown as compound 9. It was a pyrrolidone-like core structure that could undergo 
keto-enol tautomerism. For this reason, during the initial attempt to conduct the second cycle of 
virtual screening, the aim was to search for presence of this particular core structure in chemical 
compounds from databases such as SciFinder, PubChem and ZINC. All the structures found 
from all the databases mentioned previously were submitted to Glide XP docking on SPCA1d 
model. All ligand-like compounds derived from the databases were also prepared via LigPrep 
prior to any docking activity. 
 
An exact structure of the pyrrolidone-like core structure was searched and found from SciFinder. 
Another compound that had the pyrrolidone-like core structure was also found from Pubmed. 
However, both compounds were subjected to XP mode docking and did not generate satisfactory 
G scores as expected and also due to G scores were ranked in a relative term, it would be 
necessary to carry out other compound dockings in order to make more comparisons. While 
more compounds were searched from ZINC database containing the pyrrolidone structure-like 
core, BREED algorithm was trialled in an effort to generate more in silico compounds. BREED 
algorithm did this via producing hybrid molecules from selected compounds submitted by the 
user. One of the limitations with this method was that the actual chemical synthesis might be 
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difficult for the hybrid molecule such as restriction from complex compound stereochemistry and 
thus might affect the purity and yield of the compound. This was also the major reason for not 
testing one of the hybrid molecules in the FLIPR even though a reasonable G score was obtained 
at -7.166. Also the number of hybrid molecule formations might also be limited by whether if the 
ligands had swappable fragments, substituents or bonds that could be mixed and matched to 
ensure chemically and structurally-fit hybrid compounds.
163
  
 
At this stage the focus of the second cycle of molecular docking has shifted to developing a 
SERCA inhibitor due to unsatisfactory G scores obtained from above mentioned structures with 
pyrrolidone-like core rather than attempting to design a SPCA1d inhibitor. Another important 
reason of changing the focus was also to ensure a viable and effective SERCA inhibitor could be 
designed and developed where the same drug design process could be applied to design a 
SPCA1d inhibitor without doubts. This would also ensure an effective drug design process was 
established on the SERCA model which was already well-studied in the past and current 
literature than the more newly found SPCA. 
 
Since G scores were comparative terms, it was necessary to dock CPA on the SERCA1 model to 
distinguish the G score generated from CPA with the other trialled compounds. In an in silico 
environment, the G score produced from the docking of CPA on SERCA1 model would also 
behave as a control to be compared with the rest of the trialling compounds. As pointed out in 
the results section, the highest G score reached by CPA was on Sitemap-generated site 3 at -
6.786. A total of 202 hybrid molecules derived from CPA and the 26 chemical structures with 
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less pyrrolidone-like core downloaded from ZINC database were also generated. The docking of 
these hybrid molecules had a higher G score of -7.650 than both the highest G score of docking 
CPA alone and also the highest G score from docking the 26 less pyrrolidone-like structures on 
the SERCA1 model. 
 
Artemisinin was also trialled for XP docking on the SERCA1 model with the same three binding 
sites as mentioned before. The major reason for this trial was due to the discovery of artemisinin 
inhibiting the SERCA orthologue of Plasmodium falciparum in Xenopus oocytes.
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Subsequently it would be useful to investigate the effect of artemisinin on human SERCA. 
However after trialling XP docking on three Sitemap-generated sites, the G score reached was 
not as high as all the compounds trialled so far in the second round of virtual screening. Later it 
was considered to generate a receptor model based on the original SERCA orthologue of 
Plasmodium falciparum which was also known as PfATP6.  This time a crystal structure actually 
existed for PfATP6 which was found from PDB database with an ID of 1U5N. This crystal 
structure was directly imported into the Maestro interface and used. The main purpose of this 
was to observe any distinguished drug selectivity between the protozoal and human SERCAs. 
However, the result of docking artemisinin onto 1U5N actually produced a slightly lower G 
score than the one obtained from above. Both G scores obtained were below -3.5 which were 
much lower than all the previously obtained G scores in the second cycle virtual screening. The 
difference in the two highest G scores from both human and protozoal SERCA models in the 
artemisinin trial was only by a score of -1.109 which did not demonstrate observable drug 
selectivity between the two models. 
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One of the few earliest studies tested and found the anti-tumour activity of curcumin in vitro 
using Chinese Hamster Ovary cells and in vivo in mice model with Dalton’s lymphoma.167  
Another study also discovered the ability of curcumin to reduce the production of nitric oxide 
which was known to be involved in inflammatory and carcinogenic processes in cells.
168
 
Curcumin was also known to have a similar effect on the Ca
2+
-uptake activity in ER as the 
SERCA inhibitors, TG and CPA, which related to its anti-cancer property.
169
 It was proposed 
that curcumin was likely to inhibit the proprotein convertase activity by inhibiting the Ca
2+
 
activity mediated by SERCA and thus exhibited the anti-cancer property to the three colon 
cancer cell lines. Due to this evidence, curcumin in a keto-enol form was submitted for docking 
trial. On the other hand, a cyclic pyrazole analogue of curcumin was also prepared for XP 
docking. The differences between the compounds could be seen in schemes 3 and 4. The highest 
G scores between the two structures were quite close in that the G score of -5.968 for the cyclic 
pyrazole derivative of curumin was slightly higher than the G score of -5.626 for curcumin itself.  
 
BREED algorithm was again applied to the keto-enol form of curcumin in combination with 
artemisinin and the 26 less pyrrolidone-like structures found from ZINC database. A higher G 
scores was observed from the hybrid molecule than the highest G scores obtained from docking 
of curcumin in the keto-enol form. The combination of compounds used for BREED algorithm 
was then expanded to include CPA and cyclic pyrazole curcumin analogue. However this did not 
generate any new hybrid molecule as the highest G score obtained was from the same hybrid 
molecule generated from the previous BREED combination of CPA and the 26 less pyrrolidone-
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like structures. Nevertheless, as mentioned above, none of the hybrid molecules were selected for 
FLIPR testing due to difficulties discussed in the chemical synthesis process. 
 
Diallyl bisphenol A was also sent for docking trial due to the known ability of bisphenols to 
inhibit SERCA.
153,170
 One of the studies aimed to find out the structural-activity relationship of 
the inhibitory effect for 27 commercially-available bisphenols on SERCA. The major finding 
was that the presence of a variety of non-polar substituents on the two phenyl rings in bisphenols 
provided the most potent inhibitory activity of these compounds on SERCA. Examples of potent 
non-polar substituents were small alkyl groups such as allyl side chain used in the docking trial 
or halide groups. It was also found that methyl or cyclohexyl groups at the central carbon atom 
connecting the two phenyl rings would also enhance the potency of the compound. This was 
however not trialled in the docking trial in this round due to time constraint of the project. 
Another interesting study also tested the effect of bisphenol or also known as bis(2-hydroxy-3-
tert-butyl-5-methyl-phenyl)-methane and 2-aminoethoxydiphenylborate on SPCA1d and 
SERCA2b.
165
 It found that these two compounds did selectively inhibit SPCA1d more than 
SERCA2b. Bisphenol A was also tested in a similar fashion but it was found to be inhibiting 
both SPCA1d and SERCA2b at a similar level without distinguished selectivity over one or 
another. Since the current aim in this round of virtual screening was to focus on finding and 
developing a SERCA inhibitor, therefore bisphenol A with two allyl side chains was selected to 
be docked onto the SERCA1 model. As suggested by Woeste et. al., the hydrophobic 
interactions provided from the hydrophobic residues present on SERCA plus the hydrogen 
bonding from ASP254 were the two key factors in the chemical interaction between the 
bisphenol inhibitors and SERCA. Hence, the bisphenol A with two allyl groups was docked onto 
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a set grid based on these two factors as mentioned in the results section. Another binding site was 
also trialled which was the original CPA-binding site and also the three Sitemap-generated 
binding sites were also trialled. The highest G score of -6.348 reached for this bisphenol A 
compound was based on the Sitemap-generated site rather than the CPA binding site and also the 
set binding site on ASP254, ILE97 and PRO312. 
 
In the second cycle of compound selection for FLIPR testing, G scores were one of the deciding 
factors as past literature evidence on the inhibitory effect of bisphenols was also used in the 
selection process. The real outcome still lied within the actual biological experiments therefore it 
was decided to test the bisphenol A with the two allyl side groups, curcumin plus its cyclic 
pyrazole derivative. It was also worth mentioning that the G scores obtained for these three 
compounds were in fact higher than that from the CPA docking trial. It was also decided that 
soluble salt forms of bisphenol A should be considered since at this stage, chemical synthesis 
was the next step to acquire these compounds rather than obtaining from commercial source. The 
main reason to produce the soluble salt forms of the bisphenol A compound was due to FLIPR 
testing normally used DMSO as the solvent and also as the negative control, therefore the testing 
compound should at least be soluble in DMSO to aid the smooth running of FLIPR. Therefore, 
compound 15 was synthesised in the laboratory which was also useful to demonstrate any result 
difference from compound 13. Compound 10 had a similar pyrrolidone-like core present in its 
structure which would be another potential candidate for FLIPR testing. Therefore it was decided 
that five compounds in total would be synthesised and tested in FLIPR to see their effect on Ca
2+ 
signalling within the MDA-MB-231 cells. 
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The chemical synthesis process has taken similar amount of time as the molecular modelling 
stage. The production of compounds 16 and 17 only involved a short amount of time than the 
making of compound 15 due to the ability to conduct the synthesis by microwave irradiation. 
The manual column chromatography required more time input for separating the desired cyclic 
pyrazole analogue of curcumin from the unwanted chemicals. Throughout the process of making 
all five compounds, constant TLC monitoring were taken place to ensure mid-reaction 
compounds were actually correct and wanted for the end product. Final products for each 
compound were also submitted for NMR spectroscopy, mass spectroscopy (for compounds 15 
and 17), IR (for compound 15, 16 and 17 only) and X-ray diffraction for compound 16 only to 
ensure purity. 
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Figure 46  Chemical structures of compounds 10, 13, 15, 16 and 17 
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These five compounds, shown in Figure 46, have each demonstrated different Ca
2+
 response 
effects in the second batch of compound testing. Each compound was tested in three incremental 
concentrations from 1 µM, 10 µM and 100 µM. As pointed out previously, Figure 39 
representing the Ca
2+
 response from compound 17 showed an initial addition artefact where there 
was a small increase in Ca
2+
 signals. Overall, it could be confirmed that this compound did not 
affect the Ca
2+
 response in the breast cancer cells at all. On the other hand, compound 16 acted 
differently to compound 17 even though compound 16 at 1 µM also did not change the Ca2+ 
response and had a similar effect to DMSO. However, for 10 µM of compound 16, a higher Ca2+ 
response than DMSO was observed and again at the highest concentration of 100 µM, a 
significant increase of Ca
2+
 response was seen in the Figure 43. It was interesting to note that at 
10 µM, the first Ca2+ peak was not as prominent as the one for 100 µM. The second Ca2+ peak 
however at 10 µM showed an increase in Ca2+ signal after addition of Ca2+ took place and the 
peak slowly recovered but not completely. At 100 µM, the first Ca2+ peak also did not recover 
completely and quite a sharp reduction in Ca
2+
 could be noticed at around the time when more 
Ca
2+
 were added to create the second Ca
2+
 peak. Again, the same incomplete Ca
2+
 recovery curve 
was observed. This phenomenon could implicate that compound 16 acted more like a PMCA 
inhibitor rather than a SERCA inhibitor. This could also be explained by the Ca
2+ 
response 
profile produced here by compound 16 at 100 µM which did not resemble exactly as the profile 
for CPA, one of the well-studied SERCA inhibitors. Compound 16 was likely a moderately 
potent PMCA inhibitor since it required a concentration at 100 µM to elicit the higher Ca2+ 
response rather than at a smaller concentration. 
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3.4.2.2.1 Limitations from molecular modelling 
Between compounds 16 and 17, the result from the FLIPR test did not reflect the modelling 
result attained earlier where the highest G score for compound 17 was in fact higher than that for 
compound 16. This showed that the outcome from structure-based virtual screening might not 
always be reflected in the actual biological assays. Virtual screening was highly dependent on 
two essential factors; the quantity and quality of the available data used and predictive or 
discriminatory ability of the underlying screening algorithm.
171
 One of the virtual screening 
pitfalls was unrealistic assumptions and expectations. It was common to assume that the binding 
pose produced on the software screen after docking was the correct binding pose for the docked 
compound on target receptor. However, it was also highly possible that even though high G 
score was assigned to a particular ligand-receptor binding pose, the actual binding pose shown 
was in fact false. It was even mentioned that some drug discovery successes using structure-
based virtual screening might be due to pure serendipity. Another limitation within structure-
based screening was compound selection. This process was entirely based on subjectivity, even 
though G scores and MM-GBSA results were used to help with selection process. This process 
potentially could introduce bias as unselected compounds were not sent for testing and might 
produce unexpected results. This scenario could likely apply to the first round of compound 
selection where only two out of six trialled compounds were sent for FLIPR testing, the other 
four compounds missed out the opportunity to be validated due to financial reason and time 
constraints. 
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Another pitfall related to the size and diversity of the chemical compound libraries used.
171
 As 
this was only a small-scale project, only one compound library was used with the total number of 
compounds screened less than 300,000. Therefore it could also explain why the virtual screening 
results were not reflected highly in the bioassay since only one small-size and less diversified 
library of compounds was screened. In an ideal situation, more than one chemical compound 
library should be used at least with special attention paid on selecting a wide range of different 
types or classes of compounds to increase better chance of finding the hit compounds. 
 
Another likely problem in the virtual screening used in this project could come from the vendor 
libraries which provided free-access to a variety of compound libraries. These libraries 
sometimes might also contain molecules with chemically active groups or other unwanted 
functional groups that would cause interference to the high throughput screening technique used 
in the virtual screening software.
171
 This situation could not be totally ruled out for the 
compound library used in this project and could contribute to the result discrepancy between the 
virtual screening and FLIPR testing. 
 
As mentioned previously, this project was run on a small-scale basis therefore the only virtual 
screening method adopted was structure-based rather than ligand-based. Ideally, it would 
produce more potential compound candidates and likely more accurate results if more than one 
screening method was used and then to use the results collectively from all the methods used.
171
 
It was also worth to point out another downside within the virtual screening process was that 
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most of the dockings done on each receptor model were only done once and not repeated. If each 
docking was at least repeated once, this could potentially produce different docking outcomes. 
 
The other pair of compounds tested was compound 13 and 15. Compound 13 was the original 
diallyl bisphenol A and compound 15 was its analogue with two acetic acid groups attached to 
the benzene rings. From the Ca
2+
 response curve shown for compound 13, a noticeable 
incomplete Ca
2+
 recovery could be seen for the second Ca
2+
 peak at 100 µM. A similar case 
could also be seen for the first Ca
2+
 peak where there was also a slight incomplete Ca
2+
 recovery. 
The Ca
2+ 
responses for the other two concentrations unfortunately did not differ hugely from 
DMSO, set as the negative control in the second round of FLIPR testing. Consequently since 
compound 13 only began to show more prominent Ca
2+
 signals at 100 µM rather than at 10 µM 
or below, it was probably also a moderately potent Ca
2+
 pump inhibitor. The full Ca
2+
 response 
profile indicated that compound 13 might inhibit both the SERCA and PMCA pumps. By 
analysing both Ca
2+
 peaks, compound 13 might have inhibited PMCA more than SERCA since 
its first Ca
2+
 peak almost resembled that from CPA but had an incomplete Ca
2+ 
recovery. This 
could probably mean that some of the PMCA pumps were inhibited by compound 13 and were 
not available for the transit of Ca
2+
 into the ER. This could be interpreted by the incomplete Ca
2+ 
recovery to indicate some Ca
2+ 
still remained in the intracellular space.
 
The second peak had a 
sustained Ca
2+ response which was different from CPA’s complete recovery in its second Ca2+ 
peak. Again, the features observed would likely lead to the compound behaving more like a 
PMCA pump inhibitor than SERCA inhibitor. Nevertheless, compound 15 showed an opposite 
Ca
2+
 response at 100 µM when compared to compound 13. At 1 µM and 10 µM, similar Ca
2+
 
response effects were observed in both compounds 13 and 15. At these two concentrations, both 
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compounds 13 and 15 did not induce any Ca
2+
 response in the MDA-MB-231 cells. However, a 
difference in Ca
2+ 
effect was observed at 100 µM where compound 15 did not elicit any Ca
2+
 
response at all. 
 
Compound 10 also only showed an increased Ca
2+
 response at 100 µM. At 1 µM and 10 µM, the 
Ca
2+
 response were about the same as DMSO. However, overall the Ca
2+ 
signals for compound 
10 at 100 µM were still lower than CPA at 100 µM. There was a similar incomplete Ca2+ 
recovery for the first peak which was also the same for second Ca
2+
 peak. Since the compound 
was only showing effect at 100 µM, it could also be concluded that it was not a very potent Ca2+ 
pump inhibitor. From the overall Ca
2+
 signalling profile, compound 10 might also act more like a 
PMCA inhibitor than SERCA inhibitor. This was based on a sustained second Ca
2+
 peak which 
might mean that some of the Ca
2+
 added were not allowed transit into the SR via PMCA since it 
was likely inhibited by compound 10. 
 
3.4.2.2.2 Potency and structural aspects of tested compounds 
Compound 16 was the most potent out of all five compounds as it had elicited Ca
2+
 signals at 10 
µM where as other compounds only had prominent Ca2+ signals at 100 µM. This was shown in 
Figures 44 and 45. At 100 µM (Figure 45), only two out of the five compounds had explicit 
higher Ca
2+
 response on top of CPA acting as the positive control. These compounds were 
compound 16 and 13. However, for compounds at 10 µM or below (Figure 44), only compound 
16 managed to produce a higher intracellular Ca
2+ 
response than the rest of the tested compounds.  
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One of the probable explanations for the dichotomous effect between compound 13 and 15 could 
be their structural differences at the phenolic hydroxyl position. Compound 13 possessed the 
original hydroxyl group whereas compound 15 had the acetic acid group substituted at the 
hydroxyl position. Compounds 13 and 16 all had the phenol group present within their structures. 
Compound 10 had one extra hydroxyl group attached to the phenol group already present. 
Therefore the presence of phenol might be important to provide some probable inhibitory effect 
of these compounds on SERCA or PMCA. The acetic acid group within compound 15 would 
theoretically increase the solubility of the diallyl bisphenol A which would be considered as a 
useful trait during drug design process but in this case, its presence might have hindered the 
possible Ca
2+
-eliciting response in these basal-like breast cancer cells. 
 
The results from compound 16 and 17 also gave an interesting opposite effect which could 
possibly be explained by their structural differences. Compound 17 did not induce any Ca
2+
 
response where compound 16 was the most potent compound out of the five compounds tested. 
The possible inactivity from compound 17 might be due to the presence of the cyclic pyrazole 
structure instead of the keto-enol group in compound 16 since this was the only difference 
between the two compounds. Therefore from the results shown it might be possible that the 
presence of the phenol and keto-enol group within compound 16 provided the highest possible 
potency out of all tested compounds. However in order to determine the exact structure-activity 
relationship, more compound analogues would need to be synthesised and tested to confirm this 
theory thoroughly. 
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Repeat FLIPR testings were also conducted for compounds 13, 16, 17 and 10. Compound 15 was 
currently under the process of repeat testing. Consistent outcomes were seen for compounds 16, 
17 and 10 except 13 (see appendix D). The Ca
2+
 effect for both first and second Ca
2+
 peaks were 
much lower than the first test for compound 13 as shown from the FLIPR graphs. The most 
probable reason for this inconsistent repeat result for compound 13 could be due to compound 
hydrolysis which would have caused a loss in compound effect. 
 
Thus in terms of selecting the most optimal compound candidate for further drug development at 
this stage, it could be concluded that compound 16 had the most probable potential to be further 
developed to become lead compounds targeting SERCA. Both compounds 17 and 15 did not 
have any effect on the Ca
2+
 response in the breast cancer cells therefore would not be suitable 
candidates for lead compound development. Compound 10 only had the higher Ca
2+
 response at 
100 µM but when comparing its overall Ca2+ response profile; the Ca2+ signals were lower than 
both compounds 13 and 15. Therefore, compound 10 might not be one of the most ideal 
compounds to be further refined for lead development. 
 
3.4.2.3 FLIPR 
To decide if an unknown compound would be either a SERCA or SPCA inhibitor in the cells, a 
control such as CPA was used in the experiment to compare the effect of the tested compound on 
the intracellular Ca
2+
 response. Finding out the likelihood of what the tested compounds could be 
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was the major purpose of conducting the FLIPR tests in this project. From the results, it would 
then be possible to decide if the unknown compound was acting like a SERCA, SPCA or PMCA 
inhibitor. SERCA inhibitor should in theory produce a first Ca
2+
 peak resembling to that from 
CPA. SPCA inhibitor on the other hand should have a smaller first Ca
2+
 peak since there was no 
other main Ca
2+
 channels present on the Golgi apparatus apart from SPCA therefore the Ca
2+
 
leakage will be smaller than that of ER. For PMCA inhibitors, the intracellular Ca
2+ 
response 
would be more sustained and not recovered since ER Ca
2+
 store could still release Ca
2+
 into the 
cytoplasm maintaining the Ca
2+
 level. 
 
The whole process of FLIPR began with the addition of BAPTA, an intracellular Ca
2+
-chelating 
agent. This was to ensure there was no intracellular Ca
2+
 present prior to the addition of the 
chemical compounds in the MDA-MB-231 cells. Then CPA or one of the tested compounds was 
added. The addition of Ca
2+
 then took place at around 700 seconds. The purpose of the FLIPR 
test was to see if the compound selected for testing resembled the Ca
2+
 signalling profile CPA 
had on the MDA-MB-231 cells. Once this was confirmed, it would be a sound evidence for using 
the same drug designing process to design an agent to inhibit SPCA1d. 
 
The principle of the Ca
2+
 response seen in CPA could be explained by knowing that SERCA was 
inhibited by CPA as it was added into the cells. This meant no more Ca
2+ 
could be sequestered 
into the ER. This also meant that the normal Ca
2+ 
leak from ER could also not be re-sequestered. 
Hence this would cause an increase in the intracellular Ca
2+
 level. A measure of this Ca
2+
 level 
was done by FLIPR to provide the first Ca
2+
 peak shown in the graph. However since there were 
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also PMCA and other Ca
2+
 channels present on ER, this would lead to a slow entrance of the 
intracellular Ca
2+
 into the ER and thus a reduction in the Ca
2+
 response over the baseline. As 
mentioned previously, more Ca
2+
 were added at around 700 seconds by the FLIPR robot. This 
would lead to an increase in intracellular Ca
2+
 level but since the effect of CPA would wear off a 
little therefore small amount of the added Ca
2+
 would be sequestered by SERCA into the ER 
with also the access through PMCA and other Ca
2+ 
channels, therefore the second Ca
2+
 peak 
would recover at the end.  
 
The downside of the FLIPR test itself was that it was not designed to be a specific test to 
differentiate between different calcium pumps such as SERCA, SPCA and PMCA. Therefore, 
the results of the FLIPR test were only preliminary at this stage to inform the likely possibility of 
which compounds might possess the potential to inhibit either SERCA or SPCA1d. Since the 
assay method adopted in this project was understandably inadequate consequently further 
testings such as doing ATPase assay would likely affirm more promising results. The only 
probable argument of using FLIPR as the only assay method in the project was again due to 
project time constraint and also there were yet not many studies focussing on developing and 
designing a SPCA1 inhibitor in the context of targeting basal-like breast cancer. 
 
3.4.3 Conclusions and future directions 
A combination of using well-prepared chemical database, careful set-up of parameter choices 
along with any key benchmarking studies to compare screening methods and results would likely 
lead to better virtual screening outcome. A high-quality virtual screening technique, thorough 
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literature background search related to the specific drug target and presence of drug design 
expertise were some key factors required to produce viable lead compounds in drug discovery 
projects.  Therefore, to advance and improve the virtual screening process used in this study, it 
would be necessary to address all the above mentioned limitations or issues as discussed in order 
to broaden the first batch of hit compounds. Essentially, virtual screening was used to help 
reducing costs and time involved in chemical synthesis and biological testings in order to 
maximise hit compounds in an efficient manner. 
 
The initiative for this project was to find and design a candidate compound that might have the 
potential to be further refined to inhibit SPCA1d. However towards the halfway of the project 
after testing the first two virtually screened compounds, this goal has proved to be more difficult 
to be achieved therefore the aim was then adjusted to focus on finding and designing a 
compound that would inhibit SERCA since there were known SERCA inhibitors present such as 
TG and CPA, to be the reference compounds. From the second FLIPR testing of the five 
compounds, at least three out of the five tested compounds had an effect on the intracellular Ca
2+
 
signals than the two tested previously. However, both the potency and selectivity of these three 
compounds would need to be further improved to become better SERCA inhibitors. Thus 
increasing the selectivity and potency of these compounds would be the next critical step for 
future experimental work.  
 
Diallyl Bisphenol A and its derivatives, compounds 13 and 15 respectively, were known to be 
ubiquitous chemical substances used in numerous industrial polycarbonate productions.
172
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However, since both compounds 13 and 15 were known to disrupt the endocrine system and 
posed with adverse effects to pregnant women, they might not be the best candidate compounds 
to enter the next stage of compound refinement.
172,173
 Therefore even though diallyl bisphenol A 
and its derivative were not suitable lead compound candidates, they might be useful compounds 
to study the calcium signalling and relevant cellular processes involved within SERCA.  
 
The FLIPR result from testing compound 16, which was also known as curcumin, might provide 
a new direction for this particular project due to the improved Ca
2+
 response shown in the breast 
cancer cells. As discussed previously, curcumin had similar effect as TG and CPA on Ca
2+ 
signalling in colon cancer cells, it was also now widely known for its chemo-preventative and 
chemo-therapeutic effect in addition to numerous effects such as anti-inflammatory, antioxidant, 
immunomodulatory and anti-angiogenic properties.
156,169
 Hence it would be a suitable compound 
candidate for further drug development in light of inhibiting SERCA or SPCA1d to target basal-
like breast cancer. However, it was also known that curcumin had low in vivo bioavailability 
which might prevent it from being a useful and effective chemotherapeutic agent.
174
 Thus 
improving its pharmacokinetic profile, particularly oral bioavailability, might be another 
interesting aspect to be investigated in the future. 
 
It was also peculiar to see nil Ca
2+
 effect from compounds 17 and also 15. This could possibly be 
explained from a structure-activity relationship point of view as discussed previously. This 
would be another interesting aspect to find out if further work were to be carried out for this 
project. For compound 16, it might be worth submitting the compound to do Ca
2+
 ATPase assay 
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and cell viability assays to observe its effect on MDA-MB-231 cell proliferation since curcumin 
was known to have an anticancer effect. 
 
One of the other interesting aspects from the results obtained from testing the five compounds 
was that some of these compounds appeared to act more like a PMCA inhibitor. As introduced 
earlier, remodelling of PMCA isoform expressions was also highly linked to some breast or 
colon cancers. The preliminary result here might open up other different research opportunities 
to investigate the possibility of some of these compounds to target PMCA isoforms in breast or 
colon cancer cells.  
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APPENDIX A 
 
Literature review for molecular modelling methods section 
The first step was to understand the background of Ca
2+
 ATPase, especially the role of Ca
2+
 
ATPase in general and then specifically in cancer. National Centre for Biotechnology 
Information (NCBI) Pubmed was the main literature database used for literature review. 
Keywords used were cancers and SPCA1, calcium ATPase AND sarcoplasmic reticulum AND 
endoplasmic reticulum AND SPCA1. Other literature searches included work done prior from 
our collaborator from School of Pharmacy at the University of Queensland on calcium signalling 
in cancer. 
 
Further literature searches were conducted to find any human-sourced structures of Ca
2+
 ATPase. 
Keywords used in the search were X-ray crystallography, X-ray diffraction and calcium ATPase. 
A total of 81 papers were found with 14 of them from human source. Research Collaboratory for 
Structural Bioinformatics (RCSB) Protein Data Bank (PDB) website has provided protein 
structures obtained from X-ray crystallography, nuclear magnetic resonance spectroscopy and/or 
homology modelling. There were many SERCA structures found in this website.  
 
Ca
2+
 ATPase protein structures were chosen based on the protein source to see if it was from 
human and if the resolution was less than 3 Å. Actual search on PDB website has found 44 
structures for SERCA, two structures for PMCA and none for SPCA. However, none of the Ca
2+
 
ATPase structures found were from human, except one based on calmodulin- Ca
2+
 ATPase 
151 
 
complex for PMCA. Majority of the SERCA protein structures were contributed from the work 
of C. Toyoshima et. al. where majority of the protein source was from rabbit skeletal muscles. 
The keywords used to search for Toyoshima’s work on SERCA protein structures on Pubmed 
were calcium ATPase or Toyoshima C. calcium ATPase and for PDB website were calcium 
ATPase. On the other hand, further searches were carried out on Pubmed in order to find any 
SPCA structures by using keywords such as secretory pathway calcium ATPase and X-ray 
crystallography. However there were no results that matched these keywords. 
 
Since there were no SPCA protein structures available, the next step was to make a homology 
protein model of SPCA based on the structures available for SERCA. To do this, the actual 
protein sequence from a human-sourced SPCA was found on NCBI Protein. This would provide 
the actual protein backbone for the in silico SPCA protein model while using the actual SERCA 
crystal structure to provide the protein shape. 
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APPENDIX B 
 
Cell feeding methods: 
 
Dulbecco’s Modified Eagle Medium (DMEM) was warmed in 37°C water bath prior to use. 
Working surface in the hood was sprayed and wiped with 70% ethanol. Cell confluency and 
contamination were checked before cell feeding. Old media was discarded and replaced with 
10mL of fresh media. The cell flask was then placed into the incubator for further cell culture. 
 
Cell splitting methods: 
DMEM was warmed in 37°C water bath prior to use. Trypsin was left to be warmed at room 
temperature. Working surface, equipments and containers were sprayed and wiped with 70% 
ethanol prior to use. Cell culture flask was checked under the microscope for cell confluency and 
possible contamination. Old media was aspirated and replaced with PBS/EDTA (5mL) which 
was then discarded and replaced with trypsin (2mL). The cell flask was placed into the incubator 
for about half to two minutes. The flask was then checked under the microscope to ensure all 
cells were removed. Fresh media (5mL) containing PBS was added to the flask and aspirated to 
be centrifuged for two minutes at 1500rpm. Small cell pellet formed at the bottom of tube with 
supernatant removed and discarded. The cell pellet was then mixed to resuspend the cells. Fresh 
media (5mL) was added and mixed with the cells. The resuspended cell solution (0.5mL for 1:10 
dilution or 1mL for 1:5 dilution) were aspirated and dispensed into a new flask. Fresh media 
(9.5mL for 1:10 dilution or 9mL for 1:5 dilution) was then added to the resuspended cell solution. 
The cell mixture was then added into the new flask and stored in the incubator at 37°C with 5% 
CO2.  
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Cell plating methods: 
After cell splitting took place, cell count was done prior to cell plating. A 1:2 dilution (50µL of 
cell solution was added to 50µL PBS) was used for the cell count. FLIPR-specific black cell 96-
well plates were used. ViaFlo pipettor was used to aspirate and dispense 100µL of the cell 
solution into each well of the plate. The cell plate was stored in the incubator after completion 
before running the FLIPR. 
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APPENDIX C 
 
The FLIPR protocol: 
HEPES buffer solution (1L) contained potassium chloride powder (4.398g), magnesium chloride 
solution (14mL of 1M), HEPES powder (23.830g), sodium dihydrogen phosphate solution 
(12mL of 1M) and sodium bicarbonate powder (4.201g). 
 
PSS buffer solution (1L) contained HEPES stock buffer (100mL), sodium chloride solution 
9100mL or 8.182g of 1.4M), glucose powder (2.07238g) and calcium chloride solution (0.9mL 
of 2M). The actual buffer used in FLIPR was the PSS buffer without the Ca
2+
 component which 
was named PSS nominal Ca
2+
 buffer. 
 
Day 1: Cells were plated in black 96-well plate for use in FLIPR in complete growth media 
(DMEM + L-glutamine + foetal bovine serum + penicillin-streptomycin). Each well was seeded 
with 15,000 cells for 48 hour at 37
o
C, 5% CO2 (100 µL per well). 
 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A             
B             
C             
D             
E             
F             
G             
H             
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Day 2: FLIPR 
Layout: 
Reagent plate 1 
 BAPTA 3× 
 
Reagent plate 2 
 BAPTA 1×  
 
 CPA 4× 
 Compound 8 (ST4045533) 4× 
 Compound 3 (ST4081102) 4× 
 DMSO (i.e. matched to CPA) 
Reagent plate 3 
 Ca2+ 5× 
 BAPTA 1×  
 DMSO 1×/ CPA 1× 
 Compound 8 (ST4045533) 
1× 
 Compound 3 (ST4081102) 
1×  
 
 
 
REAGENT PLATE #1: BAPTA  
 
Reagent 
Initial/stock 
conc 
Final plate 
conc 3X conc 
Vol 
BAPTA 
Vol PSS 
nominal 
BAPTA 
STOCK 
100mM stock BAPTA was prepared and added 56.4mg (0.0564g) to 1mL nominal 
Ca
2+
 PSS  
BAPTA 3X 100mM 500µM 1.5mM 600µL 39.4mL 
 
Plate 1: 100 µL × 72 wells = 7.2mL 
Plate 2: 0.33mL × 24 wells (1× of BAPTA for 3 treatment groups × 8 rows of wells) ≈ 
8mL 
Plate 3: 0.33mL × 26 wells (making some extra) ≈ 9mL 
Total volume of BAPTA = 25mL therefore made 40mL in total 
 
 
 
 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA 
B BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA 
C BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA 
D BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA 
E BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA 
F BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA 
G BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA 
H BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA BAPTA 
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REAGENT PLATE #2 – COMPOUND 8 & 2 + CPA 
Stock solutions of the compounds were prepared in 100% DMSO 
1. Compound 8 (ZINC04189857) 0.0039g in 100µL 
Actual measurement: 3.596mg in 93.4µL of DMSO 
 
2. Compound 3 (ZINC08846492) 0.0048g in 100µL 
Actual measurement: 3.657mg in 75.6 µL of DMSO 
 
3. Stock CPA solution was made up at 100mM. 
 
Both compound 8 and 3 were in white powder form placed in amber glass vials. Due to static 
charges inside the vial, the powders were attached to the sides of the vial during the weighing 
process. Therefore, the actual amounts of the compounds weighed were less than expected. 
Compound molar concentrations were reduced to increase solubility by diluting stock solution of 
100mM with DMSO to 10mM (1:10 dilution) for C1, to 3mM (1:33) for C2 and to 10mM (1:10) 
for CPA. 
Agonists 
Initial
/ 
stock 
conc 
Final 
conc 4× conc  
Volume 
agonist  
Volume 
PSS/ 
BAPTA 3× 
Volume 
PSS 
nominal 
Ca
2+
 
Volume 
DMSO 
 
TOTAL 
volume 
Compound 8 
ZINC04189857 
 
10mM 10µM 40µM 4µL 0.333mL 0.663mL 0µL 1mL 
40µM 3µM 12µM 0.3mL 0.333mL 0.364mL 2.8µL 1mL 
12µM 1µM 4µM 0.333mL 0.333mL 0.331mL 2.68µL 1mL 
4µM 0.3µM 1.2µM 0.3mL 0.333mL 0.364mL 2.8µL 1mL 
1.2µM 0.1µM 0.4µM 0.333mL 0.333mL 0.331mL 2.68µL 1mL 
0.4µM 0.03µ
M 0.12µM 0.3mL 
0.333mL 0.364mL 2.8µL 1mL 
0.12µ
M 
0.01µ
M 0.04µM 0.333mL 
0.333mL 0.331mL 2.68µL 1mL 
0µM 0µM 0µM 0mL 0.333mL 0.663mL 4µL 1mL 
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Agonists 
Initial
/ 
stock 
conc 
Final 
conc 4× conc  
Volume 
agonist  
Volume 
PSS/ 
BAPTA 3× 
Volume 
PSS 
nominal 
Ca
2+
 
Volume 
DMSO 
 
TOTAL 
volume 
Compound 3 
ZINC08846492 
3mM 3µM 12µM 4µL 0.333mL 0.663mL 0µL 1mL 
12µM 1µM 4µM 0.333mL 0.333mL 0.331mL 2.68µL 1mL 
4µM 0.3µM 1.2µM 0.3mL 0.333mL 0.364mL 2.8µL 1mL 
1.2µM 0.1µM 0.4µM 0.333mL 0.333mL 0.331mL 2.68µL 1mL 
0.4µM 0.03µ
M 0.12µM 0.3mL 
0.333mL 0.364mL 2.8µL 1mL 
0.12µ
M 
0.01µ
M 0.04µM 0.333mL 
0.333mL 0.331mL 2.68µL 1mL 
0µM 0µM 0µM 0mL 0.333mL 0.663mL 4µL 1mL 
 
 
 
 
 
 
Agonists Initial/ 
stock 
conc 
Final 
conc 4× conc  
Volume 
agonist  
Volume 
PSS/ 
BAPTA 3× 
Volume 
PSS 
nominal 
Ca2+ 
Volume 
DMSO 
 
TOTAL 
volume 
CPA 10mM 10µM 40µM 4µL 0.333mL 0.663mL 0µL 1mL 
40µM 3µM 12µM 0.3mL 0.333mL 0.364mL 2.8µL 1mL 
12µM 1µM 4µM 0.333mL 0.333mL 0.331mL 2.68µL 1mL 
4µM 0.3µM 1.2µM 0.3mL 0.333mL 0.364mL 2.8µL 1mL 
1.2µM 0.1µM 0.4µM 0.333mL 0.333mL 0.331mL 2.68µL 1mL 
0.4µM 0.03µM 0.12µM 0.3mL 0.333mL 0.364mL 2.8µL 1mL 
0.12µM 0.01µM 0.04µM 0.333mL 0.333mL 0.331mL 2.68µL 1mL 
0µM 0µM 0µM  0mL 0.333mL 0.663mL 4µL  1mL 
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REAGENT PLATE #3:  
2mM Ca
2+ 
was used for each well 
Final well 
conc 
Initial 
conc 
Final 
Ca
2+ 
plate 
conc 
5× 
conc 
Vol 
Ca
2+
 
Vol PSS 
3× 
BAPTA 
Vol PSS 
4× DMSO/ 
4× CPA/ 
4×Cpd 1/ 
4× Cpd 2 
Vol PSS 
nominal 
 
TOTAL 
volume 
10µM 2M 2mM 10mM 
 
 
5µL 
 
 
 
 
 
 
 
 
0.333mL 
 
 
 
 
 
0.25mL CPA 
/Cpd 1 
/Cpd 2 
 
 
 
0.412mL 
 
 
 
 
 
 
 
 
1mL 
3µM 2M 2mM 10mM 
1µM 2M 2mM 10mM 
0.3µM 2M 2mM 10mM 
0.1µM 2M 2mM 10mM 
0.03µM 2M 2mM 10mM 
0.01µM 2M 2mM 10mM 
0µM 0M 0mM 0mM     
 
 
CPA 
 
Compound 8 
 
Compound 3 
 
 
1 2 3 4 5 6 7 8 9 10 11 12 
10µM A    
   PSS PSS PSS PSS PSS PSS 
3µM B    
      PSS PSS PSS 
1µM C    
      PSS PSS PSS 
0.3µM D    
      PSS PSS PSS 
0.1µM E    
      PSS PSS PSS 
0.03µM F    
      PSS PSS PSS 
0.01µM G    
      PSS PSS PSS 
0µM H    
      PSS PSS PSS 
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Twenty six batches of 130µL Ca
2+
 plus 8.58mL PSS 3× BAPTA and 10.79mL PSS nominal Ca
2+
 
(19.5mL in total) were prepared. This was followed by adding 750 µL of Ca
2+
 + PSS 3×  
BAPTA + PSS nominal Ca
2+
 into each tube (for plate 2) then added 250µL of PSS 
DMSO/CPA/Cpd1/Cpd2 to each tube (for plate 3) – made from plate 2 for matching 
concentrations. 
 
 
 
FLIPR solutions were made fresh on the day of running FLIPR and PSS buffer was warmed to 
room temperature. The components of each FLIPR solutions were shown as below. 
PSS/Ca
2
+ Bovine serum albumin (BSA) 
BSA, fatty acid free (4°C) ........................................ 0.06g 
PSS/Ca
2+
 .................................................................. 20mL 
 
Fluo-4-AM (4mM) 
Fluo-4 (Invitrogen) ...................................................................................... 1 tube 
DMSO .......................................................................................................... 11.4μL 
wrap in foil; store at -22°C 
 
 
 
 
CPA 
 
Compound 8 
 
Compound 3 
 
 
1 2 3 4 5 6 7 8 9 10 11 12 
10µM A Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ 
PSS
 
PSS PSS PSS
 
PSS PSS 
3µM B Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ 
PSS
 
PSS PSS 
1µM C Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ 
PSS
 
PSS PSS 
0.3µM D Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ 
PSS
 
PSS PSS 
0.1µM E Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ 
PSS
 
PSS PSS 
0.03µM F Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ 
PSS
 
PSS PSS 
0.01µM G Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ 
PSS
 
PSS PSS 
0µM H Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ Ca2+ 
PSS
 
PSS PSS 
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Fluo-4-AM (4μM) (dye loading solution) 
Fluo-4 (4mM)........................................................... 8.5μL 
Growth media........................................................... 8.5mL 
 
Cell loading 
The media was removed and Fluo-4 was loaded to each well using Viaflo pipettor and the plate 
was incubated for 30 minutes. The media was again removed and the plate was further incubated 
for 15 minutes at room temperature in PSS/Ca
2+
 in foil. 
 
Cell washing 
 
Cells were washed twice with PSS/Ca
2+
+BSA (100μL/well) and once with PSS/nominal Ca2+ 
(100μL/well). PSS/nominal Ca2+ (100μL/well) were added into each well and the plate was 
submitted to FLIPR to begin the run. The reagents were added in the order of plate 1, plate 2 and 
plate 3 to the cell plate. 
 
 
Final reagent plate layout  
 
 
CPA 
 
Compound 8 
 
Compound 3 
 
 
1 2 3 4 5 6 7 8 9 10 11 12 
10µM A 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
PSS
 
PSS PSS PSS.
 
PSS PSS 
3µM B 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
PSS
 
PSS PSS 
1µM C 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
PSS
 
PSS PSS 
0.3µM D 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
PSS
 
PSS PSS 
0.1µM E 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
PSS
 
PSS PSS 
0.03µM F 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
PSS
 
PSS PSS 
0.01µM G 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
PSS
 
PSS PSS 
0µM H 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
BAPTA 
Ca
2+
 
PSS
 
PSS PSS 
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APPENDIX D - FLIPR repeats for compounds 10, 13, 16 and 17 
1. Compound 13 – three repeats in order of appearance 
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3. Compound 10 – three repeats in order of appearance 
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4. Compound 17 – three repeats in order of appearance 
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APPENDIX E – Homology model sequence alignments 
 
SPCA1d model – Homolog: 1SU4 
  
SPCA2 model – Homolog: 1IW0 
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SERCA1 model – Homolog: 3AR5 
 
 
SERCA2 model – Homolog: 3AR4 
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SERCA3 model – Homolog: 3AR7 
 
